Original Article
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
N Engl J Med 2001; 345:1809-1817December 20, 2001
- Abstract
Background
Patients with arthritis and vascular disease may receive both low-dose aspirin and other nonsteroidal antiinflammatory drugs. We therefore investigated potential interactions between aspirin and commonly prescribed arthritis therapies.
Methods
We administered the following combinations of drugs for six days: aspirin (81 mg every morning) two hours before ibuprofen (400 mg every morning) and the same medications in the reverse order; aspirin two hours before acetaminophen (1000 mg every morning) and the same medications in the reverse order; aspirin two hours before the cyclooxygenase-2 inhibitor rofecoxib (25 mg every morning) and the same medications in the reverse order; enteric-coated aspirin two hours before ibuprofen (400 mg three times a day); and enteric-coated aspirin two hours before delayed-release diclofenac (75 mg twice daily).
Results
Serum thromboxane B2 levels (an index of cyclooxygenase-1 activity in platelets) and platelet aggregation were maximally inhibited 24 hours after the administration of aspirin on day 6 in the subjects who took aspirin before a single daily dose of any other drug, as well as in those who took rofecoxib or acetaminophen before taking aspirin. In contrast, inhibition of serum thromboxane B2 formation and platelet aggregation by aspirin was blocked when a single daily dose of ibuprofen was given before aspirin, as well as when multiple daily doses of ibuprofen were given. The concomitant administration of rofecoxib, acetaminophen, or diclofenac did not affect the pharmacodynamics of aspirin.
Conclusions
The concomitant administration of ibuprofen but not rofecoxib, acetaminophen, or diclofenac antagonizes the irreversible platelet inhibition induced by aspirin. Treatment with ibuprofen in patients with increased cardiovascular risk may limit the cardioprotective effects of aspirin.
Media in This Article
Figure 1
Flow Chart of Study Protocols.Figure 5
The Effect of Aspirin Alone and of Ibuprofen plus Aspirin on Platelet Cyclooxygenase-1.Article Activity
- Article
Nonsteroidal antiinflammatory drugs (NSAIDs) are commonly prescribed,1 and the use of aspirin has increased since it was shown to reduce the risk of myocardial infarction and stroke.2,3 Aspirin acts by irreversibly acetylating a serine residue at position 529 in platelet prostaglandin G/H synthase,4 an enzyme colloquially known as cyclooxygenase. The predominant product of cyclooxygenase in platelets is thromboxane A2.5 The anucleate platelet affords a unique target for aspirin, since once cyclooxygenase has been acetylated by aspirin, the substrate's access to its active site is impeded for the lifetime of the platelet. Thus, the formation of thromboxane A2 requires the synthesis of new platelets, which are regenerated at a daily rate of approximately 10 percent.6,7
Although aspirin is effective in the secondary prevention of important vascular events,2,3 the effectiveness of traditional NSAIDs in this respect is unknown. Prospective, controlled trials have been limited,8,9 and initial case–control analysis suggests that NSAIDs do not reduce the risk of a first myocardial infarction.10 NSAIDs, unlike aspirin, bind reversibly at the active site of the enzyme, usually depressing platelet thromboxane formation to the degree that platelet function is impaired for only a portion of the dosing interval.11
The form of cyclooxygenase that is produced in human platelets, cyclooxygenase-1,4,12 has been crystallized,13 and the structural basis of inhibition by both aspirin14 and NSAIDs15 has been elucidated. Both the aspirin- and the NSAID-binding sites lie within a narrow hydrophobic channel within the core of the enzyme. The potential for a competitive interaction between aspirin and NSAIDs afforded by these structural relations is supported by evidence from previous studies.16,17
Because many patients take both NSAIDs and aspirin,18 we undertook a study to address in a more detailed fashion the possibility of a pharmacodynamic interaction between the two. First, we performed a controlled study to determine whether such an interaction does indeed exist. We then determined whether the effects of an aspirin regimen of the type commonly used for cardioprotection would be influenced by a clinically relevant NSAID regimen and whether the effects would extend to other compounds of the NSAID class. We also examined the interaction of aspirin with a specific inhibitor of cyclooxygenase-2, a new subclass of NSAID that selectively targets a second cyclooxygenase isozyme thought to be of most relevance to prostanoid formation in inflammation and cancer.19 Finally, we investigated the interaction of aspirin with acetaminophen, since the effects of acetaminophen on cyclooxygenase activity remain controversial.20,21
Methods
Study Subjects
The study protocols were approved by the institutional review board and the General Clinical Research Center advisory committee of the University of Pennsylvania School of Medicine. Written informed consent was obtained from all study subjects. The subjects were between 18 and 65 years of age and within 30 percent of ideal body weight and had an unremarkable medical history, physical examination, and routine hematologic and biochemical studies. Smokers and subjects with a bleeding disorder, an allergy to aspirin or any other NSAID, or a history of any gastrointestinal or cerebrovascular disease were excluded. Subjects abstained from the use of aspirin and other NSAIDs for at least two weeks before enrollment.
Crossover Study with Single Daily Doses
Study Design, Treatments, and Assessment
The first study was a randomized, crossover study of combinations of single daily doses of two treatments for 6 days, with a washout period of at least 14 days (Figure 1Figure 1
Flow Chart of Study Protocols.). One group received aspirin (81 mg) two hours before ibuprofen (400 mg) for six days and, after the washout period, the same medications in the reverse order. Another group received aspirin two hours before acetaminophen (1000 mg) for six days and then the same medications in the reverse order. And a third group received aspirin two hours before the cyclooxygenase-2 inhibitor rofecoxib (25 mg) and then the same medications in the reverse order.The inhibition of platelet cyclooxygenase-1 was assessed by measurements of serum thromboxane B2.22 Platelet aggregation induced by arachidonic acid was measured in platelet-rich plasma ex vivo.11 Cyclooxygenase-2 activity was assessed through the measurement of the formation of lipopolysaccharide-stimulated prostaglandin E2 in whole blood.23 Measurements were performed immediately before the administration of the first drug and immediately before the administration of the second drug on day 1, and 2, 6, 12, and 24 hours after the administration of the first drug on day 1 and day 6. Urinary 2,3-dinor-6-keto prostaglandin F1α, an index of prostaglandin I2 biosynthesis,24 was assessed during the 12 hours before the administration of the first dose of study medication and in three sequential collections after the first study drug was administered (from hour 0 to hour 6, from hour 6 to hour 12, and from hour 12 to hour 24) on days 1 and 6. Biochemical studies were performed by staff members who were blinded to the treatment-group assignments.
Statistical Analysis
The primary hypothesis was that administering ibuprofen before aspirin would antagonize the irreversible effects of aspirin, as assessed by the measurement of serum thromboxane B2 (primary end point) and platelet aggregation (secondary end point) 24 hours after the administration of the first study drug on day 6 of combination therapy.
This study had a six-factor, balanced, incomplete block design with two nonrepeated factors (treatment group and sequence) and four repeated factors (period, order, day, and hour). A two-by-two crossover design with factor sequence, period, and order was considered for each stratum defined in terms of the treatment group, the day, and the hour. An analysis of variance, appropriate for a two-by-two crossover design, was produced with the use of the mixed and general linear model procedures. The estimate of sample size was based on the analysis of the effects of aspirin in subjects in the ibuprofen group. It was anticipated on the basis of previous studies that a sample size of 18 (6 per group) would afford a power in excess of 90 percent to detect a difference of 20 percent or greater in serum thromboxane measurements and platelet aggregation, with two-tailed tests of the hypothesis associated with a type I error rate of less than 0.05 for all the main effects.
Parallel-Group Study with Multiple Daily Doses
Study Design, Treatments, and Assessment
We also performed a parallel-group, randomized, open-label, six-day study in which one group was given enteric-coated aspirin (81 mg) at 8 a.m. and ibuprofen (400 mg) at 10 a.m., 3 p.m., and 8 p.m. and another group was given enteric-coated aspirin at 8 a.m. and delayed-release diclofenac (75 mg) at 10 a.m. and 6 p.m. (Figure 1). The inhibition of platelet cyclooxygenase-1 activity was assessed by measurement of serum thromboxane B2 and platelet aggregation.11,22
Statistical Analysis
The primary hypothesis was that ibuprofen or diclofenac would antagonize the irreversible effects of enteric-coated aspirin 24 hours after the administration of the first study drug on day 6 of the combination therapy. The estimate of sample size was based on the difference we found in the first study between the serum thromboxane B2 level after the administration of aspirin before ibuprofen as compared with the administration of these drugs in reverse order. It was anticipated that a sample of five subjects per group would afford a power in excess of 90 percent to detect the main effect, with two-tailed tests of the hypothesis and a type I error rate of 0.05.
Results
Crossover Study with Single Daily Doses
Three subjects in the first study who withdrew before receiving the study drug were replaced; all subjects who began receiving drugs completed the study according to the protocol. One subject reported an episode of epistaxis, and a second had a drop in hemoglobin of 1 g per liter. Analysis of variance revealed that the randomized order of administration did not affect the study end points. This indicates that there was no carryover effect during the washout period. Therefore, the results were pooled according to the order of dosing.
In the single-dose-ibuprofen group, subjects who took aspirin first had at least 98 percent inhibition of serum thromboxane B2 up to 24 hours after dosing on day 6 (Figure 2AFigure 2
Mean Inhibition of Platelet Cyclooxygenase-1 Activity, as Assessed by Measurement of Serum Thromboxane B2 (Panel A) and Inhibition of Platelet Aggregation (Panel B) in Subjects Taking Ibuprofen before Aspirin or Aspirin before Ibuprofen on Day 6 of Prolonged Dosing.). When the same subjects took ibuprofen before aspirin, serum thromboxane B2 was more than 97 percent inhibited two hours after the administration of ibuprofen on day 6, but it later recovered, as would be expected after the administration of a reversible cyclooxygenase-1 inhibitor11 such as ibuprofen (Figure 2A). Twenty-four hours after the administration of the first study drug on day 6, the mean (±SD) degree of inhibition of serum thromboxane B2 was 99±0.3 percent when the subjects had taken aspirin before ibuprofen and 53±7 percent when the subjects had taken ibuprofen before aspirin (P<0.001).Platelet aggregation was also irreversibly inhibited when subjects took aspirin before ibuprofen and reversibly inhibited when subjects took ibuprofen before aspirin (Figure 2B). Twenty-four hours after the administration of the first study drug on day 6, the mean degree of inhibition of platelet aggregation was 98±1 percent in subjects who had taken aspirin before ibuprofen and 2±1 percent in subjects who had taken ibuprofen before aspirin (P<0.001).
In the acetaminophen group, the inhibition of serum thromboxane B2 in subjects who took aspirin before acetaminophen was similar to that observed in subjects in the single-dose-ibuprofen group who took aspirin before ibuprofen, with at least 96 percent inhibition up to 24 hours after treatment on day 6. Pretreatment with acetaminophen did not alter the antiplatelet effect of aspirin. The inhibition of serum thromboxane B2 was similar on day 6 regardless of whether subjects had taken aspirin or acetaminophen first.
The inhibition of platelet aggregation on day 6 in subjects who had taken aspirin before acetaminophen was also similar to the inhibition in those who had taken acetaminophen before aspirin. Platelet aggregation was unaltered two hours after the administration of acetaminophen and before the administration of aspirin on day 1, when serum thromboxane B2 was inhibited by 44±14 percent. The failure of acetaminophen to inhibit platelet aggregation25 — given its limited degree of inhibition of platelet cyclooxygenase-1 activity — was expected.7,26
In the rofecoxib group, the patterns of serum thromboxane B2 production (Figure 3AFigure 3
Mean Inhibition of Platelet Cyclooxygenase-1 Activity, as Assessed by Measurement of Serum Thromboxane B2 (Panel A) and Inhibition of Platelet Aggregation (Panel B) in Subjects Taking Rofecoxib before Aspirin or Aspirin before Rofecoxib on Day 6 of Prolonged Dosing.) and platelet aggregation (Figure 3B) when the subjects took aspirin first were similar to the patterns found when subjects took rofecoxib first. There was no inhibition of platelet cyclooxygenase-1 activity or platelet aggregation two hours after the administration of rofecoxib on day 1.27,28 In all three groups, subjects who took aspirin before the other drug showed no inhibition of cyclooxygenase-2 activity in ex vivo studies, as reflected by the level of lipopolysaccharide-stimulated prostaglandin E2 two hours after the administration of low-dose aspirin (and before the administration of the other drug) on day 1 (Table 1Table 1
Inhibition of Whole-Blood Lipopolysaccharide-Stimulated Prostaglandin E2.). Thus, the pattern of inhibition of cyclooxygenase-2 activity reflects inhibition by the additional therapy. Inhibition of cyclooxygenase-2 activity by ibuprofen, an isoform-nonspecific cyclooxygenase inhibitor, approached 80 percent two hours after the administration of the first study drug on day 6 and was rapid in onset and transient, as anticipated on the basis of the pharmacokinetic profile of the drug29 (Table 1). Acetaminophen was also an inhibitor of cyclooxygenase-2 activity ex vivo, attaining 53±8 percent inhibition two hours after the administration of the first study drug on day 6 (Table 1). Rofecoxib caused prolonged and substantial inhibition of cyclooxygenase-2 activity ex vivo (more than 80 percent 12 hours after the administration of the first study drug on day 6) — an effect that is consistent with the drug's long half-life19,30 (Table 1).The effects of the drugs on urinary 2,3-dinor-6-keto prostaglandin F1α resembled their effects on the lipopolysaccharide-induced formation of prostaglandin E2 ex vivo (Table 2Table 2
Inhibition of Urinary 2,3-dinor-6-keto Prostaglandin F1α.). This finding was expected, given that cyclooxygenase-2 is the predominant source of 2,3-dinor-6-keto prostaglandin F1α in healthy persons.27,28 Parallel-Group Study with Multiple Daily Doses
One subject in the parallel-group study was replaced because of viral illness and the use of NSAIDs that were not part of the study regimen. When subjects received enteric-coated aspirin before the morning dose of ibuprofen, the serum thromboxane B2 levels (Figure 4AFigure 4
Mean Inhibition of Platelet Cyclooxygenase-1 Activity, as Assessed by Measurement of Serum Thromboxane B2 (Panel A) and Inhibition of Platelet Aggregation (Panel B) in Subjects Taking Enteric-Coated Aspirin (81 mg) Two Hours before Either Ibuprofen (400 mg Three Times Daily) or Delayed-Release Diclofenac (75 mg Twice Daily) on Day 6 of Prolonged Dosing.) and platelet aggregation (Figure 4B) recovered, as is consistent with the reversible inhibition of cyclooxygenase-1 activity and antagonism of aspirin's irreversible effect by the multiple-dose NSAID regimen. By contrast, the sustained inhibitory effect of enteric-coated aspirin on serum thromboxane B2 and platelet aggregation was not altered by the administration of diclofenac (Figure 4). Thus, 24 hours after the administration of the first study drug on day 6, the degree of inhibition of serum thromboxane B2 was 92±3.8 percent when diclofenac was given after enteric-coated aspirin, as compared with 67±9.5 percent when multiple doses of ibuprofen were given after aspirin (P<0.05) (Figure 4). Single doses of delayed-release diclofenac (75 mg), given two hours before aspirin (81 mg), for six days also produced no antagonism of the irreversible antiplatelet effect of aspirin (data not shown).Discussion
Aspirin reduces the incidence of recurrent myocardial infarction and stroke.2,3 Although it also reduces significantly the incidence of a first nonfatal myocardial infarction,31,32 this benefit is balanced by its propensity to induce gastrointestinal hemorrhage.3 NSAIDs are available over the counter for various indications and are prescribed widely for symptomatic relief for patients with arthritis.1 More recently, selective inhibitors of the cyclooxygenase-2 isozyme have been shown to cause fewer gastrointestinal complications than traditional NSAIDs.33
Neither traditional NSAIDs nor selective cyclooxygenase-2 inhibitors would be expected to afford substantial cardioprotection. NSAIDs inhibit the activity of the cyclooxygenase-1 isoform in the platelet, but most have actions that do not persist throughout the dosing interval rather than providing an irreversible effect like that of aspirin.5,15 The relation between the inhibition of platelet cyclooxygenase-1–dependent thromboxane A2 generation and the inhibition of thromboxane-dependent platelet function is nonlinear,7,26 so the inhibition of platelet aggregability commonly does not persist during dosing with NSAIDs. Recently, it has been suggested that naproxen may differ from other NSAIDs in sustaining functionally important degrees of inhibition of platelet cyclooxygenase-1 activity throughout the dosing interval.34 However, whether naproxen has a cardioprotective role remains controversial.10 Thus, many patients taking NSAIDs also take aspirin, usually in low doses, for cardioprotection. Platelet cyclooxygenase-1 activity is unaffected by the use of cyclooxygenase-2 inhibitors.28 Concern about the depression of vascular prostaglandin I2 production in the absence of concomitant platelet inhibition19,27,35 has enhanced awareness of the need for adjuvant antiplatelet therapy in appropriate patients who are receiving cyclooxygenase-2 inhibitors.
We wished to address the hypothesis that an NSAID, but not a cyclooxygenase-2 inhibitor, might competitively inhibit the ability of low-dose aspirin to cause an irreversible inhibition of platelet function. Low-dose aspirin cumulatively inactivates cyclooxygenase in the anucleate platelet during prolonged dosing.36,37 Pretreatment with ibuprofen did, indeed, block the inhibition of platelet cyclooxygenase-1 activity and the impairment of platelet aggregation achieved by aspirin with prolonged dosing. These results are consistent with competitive inhibition by NSAIDs of the access of aspirin to the acetylation site in platelet cyclooxygenase-1 (Figure 5Figure 5
The Effect of Aspirin Alone and of Ibuprofen plus Aspirin on Platelet Cyclooxygenase-1.).14 This interaction may be clinically relevant, because platelet aggregation may be sustained through the thromboxane pathway even if only 10 to 15 percent of the platelets remain functional. In our first study, this effect of ibuprofen could be bypassed by giving subjects aspirin two hours before a single daily dose of ibuprofen. However, in our second study, we simulated a more clinically relevant ibuprofen dosing regimen. Ibuprofen was administered three times per day, and an enteric-coated preparation of aspirin was administered once daily, as it is commonly used for cardioprotection in patients taking NSAIDs. Under these circumstances, the administration of aspirin before the morning dose of ibuprofen failed to circumvent the interaction. Thus, the inhibitory effects of daily low-dose aspirin on platelets are competitively inhibited by the prolonged use of multiple daily doses of ibuprofen, even when aspirin is administered before the first dose of the NSAID.By contrast, the prolonged administration of a typical regimen of delayed-release diclofenac (twice daily) did not inhibit the antiplatelet effect of enteric-coated aspirin. This lack of interaction may reflect the lower potency and shorter duration of action of the diclofenac regimen. In studies of short-term dosing with delayed-release diclofenac, we found that the degree of inhibition of serum thromboxane B2 was 87±6.2 percent two hours after dosing and had returned to 54.6±7.4 percent inhibition within six hours. By contrast, inhibition was more pronounced two hours after short-term dosing with ibuprofen (94.6±2.3 percent, P<0.05) and was more sustained six hours after dosing with ibuprofen (81.4±4.1 percent, P<0.05) than after the administration of delayed-release diclofenac. An alternative hypothesis is that the diclofenac and ibuprofen afford differential impedance of the access of aspirin to the serine residue at position 529 in prostaglandin G/H synthase. Although ibuprofen, flurbiprofen, indomethacin, and suprofen all bind cyclooxygenase-1 in superimposable configurations,15 the binding of diclofenac may be spatially segregated from such inhibitors within the hydrophobic channel.38,39 However, the relevance of this observation and of the kinetic distinctions between the two drugs to our findings regarding platelet cyclooxygenase-1 remain to be addressed directly.
As expected,40 rofecoxib did not influence the effects of aspirin. Cyclooxygenase-2 inhibitors bind to a side pocket that is present in the hydrophobic channel of cyclooxygenase-2 but not in that of cyclooxygenase-1.41 Consideration of the cost of treatment with traditional NSAIDs and recognition of the failure of selective cyclooxygenase-2 inhibitors to afford cardioprotection have raised interest in their combination with aspirin.19
Finally, we obtained detailed information on the effect of acetaminophen on cyclooxygenase function. Although acetaminophen is recommended for osteoarthritis of the hip and knee42 and is widely used as an antipyretic, it is less effective than traditional NSAIDs as an antiinflammatory agent.43,44 We found that, at a dose of 1000 mg, acetaminophen is a weak, reversible, isoform-nonspecific cyclooxygenase inhibitor. Such limited inhibition of cyclooxygenase-1 does not inhibit platelet function. Moreover, since competitive inhibition at the active site of cyclooxygenase would be expected to be concentration-dependent and saturable,15 it is perhaps not surprising that acetaminophen also fails to modify the antiplatelet action of aspirin. Higher doses of acetaminophen or regimens entailing multiple daily doses have been reported to have a gastrointestinal adverse-effect profile that resembles that of traditional NSAIDs.45 It remains to be determined whether such regimens might afford levels of cyclooxygenase inhibition similar to those attained with 400 mg of ibuprofen and have similar effects on the action of aspirin.
In summary, our findings suggest that commonly used analgesics may modulate the cardioprotective effects of low-dose aspirin to differing degrees. A clinical dosing regimen of ibuprofen may competitively inhibit the sustained inhibitory effect on platelets that underlies the cardioprotective property of aspirin. This observation is likely to extend to a second NSAID, indomethacin,15,16 but not to diclofenac or the cyclooxygenase-2 inhibitor rofecoxib. Finally, acetaminophen is a weak, reversible, isoform-nonspecific cyclooxygenase inhibitor.
Supported in part by grants (M01RR00040, HL 5400, and HL 62250) from the National Institutes of Health and by funds from Bayer Consumer Care.
Dr. Catella-Lawson is an employee of Merck.
Source Information
From the EUPenn Group of Investigators at the Center for Experimental Therapeutics (F.C.-L., S.D., B.T., G.A.F.), the Division of Cardiology (M.P.R.), and the General Clinical Research Center (F.C.-L., S.C.K., A.J.C., S.N.V., G.A.F.), University of Pennsylvania School of Medicine, Philadelphia.
Address reprint requests to Dr. FitzGerald at the University of Pennsylvania School of Medicine, 153 Johnson Pavilion, 3620 Hamilton Walk, Philadelphia, PA 19104-6084, or at garret@spirit.gcrc.upenn.edu.
- References
References
1
Singh G ,Triadafilopoulos G . Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999;26:Suppl 56:18-24
Web of Science2
Antiplatelet Trialists' Group. Prevention of death, myocardial infarction and stroke by antiplatelet therapy in high risk patients. BMJ (in press).
3
Patrono C ,Coller B ,Dalen JE , et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001;119:Suppl:39S-63S
CrossRef | Web of Science | Medline4
Funk CD ,Funk LB ,Kennedy ME ,Pong AS ,FitzGerald GA . Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J 1991;5:2304-2312
Web of Science | Medline5
FitzGerald GA . Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 1991;68:11B-15B
CrossRef | Web of Science | Medline6
Patrono C ,Ciabattoni G ,Patrignani P , et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985;72:1177-1184
CrossRef | Web of Science | Medline7
Di Minno G ,Silver MJ ,Murphy S . Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood 1983;61:1081-1085
Web of Science | Medline8
Brochier ML . Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction: the Flurbiprofen French Trial. Eur Heart J 1993;14:951-957
CrossRef | Web of Science | Medline9
Fornaro G ,Rossi P ,Mantica PG , et al. Indobufen in the preventionof thromboembolic complications in patients with heart disease: a randomized, placebo-controlled, double-blind study. Circulation 1993;87:162-164
Web of Science | Medline10
Garcia Rodriguez LA ,Varas C ,Patrono C . Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000;11:382-387
CrossRef | Web of Science | Medline11
Pedersen AK ,FitzGerald GA . Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing. Clin Pharmacol Ther 1985;37:36-42
CrossRef | Web of Science | Medline12
Patrignani P ,Sciulli MG ,Manarini S ,Santini G ,Cerletti C ,Evangelista V . COX-2 is not involved in thromboxane biosynthesis by activated human platelets. J Physiol Pharmacol 1999;50:661-667
Web of Science | Medline13
Picot D ,Loll PJ ,Garavito RM . The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 1994;367:243-249
CrossRef | Web of Science | Medline14
Loll PJ ,Picot D ,Garavito RM . The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 1995;2:637-643
CrossRef | Medline15
Loll PJ ,Picot D ,Ekabo O ,Garavito RM . Synthesis and use of iodinated nonsteroidal antiinflammatory drug analogs as crystallographic probes of the prostaglandin H2 synthase cyclooxygenase active site. Biochemistry 1996;35:7330-7340
CrossRef | Web of Science | Medline16
Livio M ,Del Maschio A ,Cerletti C ,de Gaetano G . Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclo-oxygenase activity. Prostaglandins 1982;23:787-796
CrossRef | Web of Science | Medline17
Rao GHR ,Johnson GG ,Reddy KR ,White JG . Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin. Arteriosclerosis 1983;3:383-388
CrossRef | Medline18
Pathmakanthan S ,O'Donovan DG ,Sheehan KM ,Murray FE . Prospective evaluation of the utilization of aspirin and non-steroidal anti-inflammatory drugs in acute medical admissions. Ir Med J 1998;91:58-60
Medline19
FitzGerald GA ,Patrono C . The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-442
Full Text | Web of Science | Medline20
Green K ,Drvota V ,Vesterqvist O . Pronounced reduction of in vivo prostacyclin synthesis in humans by acetaminophen (paracetamol). Prostaglandins 1989;37:311-315
CrossRef | Web of Science | Medline21
Vesterqvist O ,Green K . Urinary excretion of 2,3-dinor-thromboxane B2 in man under normal conditions, following drugs and during some pathological conditions. Prostaglandins 1984;27:627-644
CrossRef | Web of Science | Medline22
Alessandrini P ,Avogaro P ,Bittolo Bon G ,Patrignani P ,Patrono C . Physiologic variables affecting thromboxane B2 production in human whole blood. Thromb Res 1985;37:1-8
CrossRef | Web of Science | Medline23
Patrignani P ,Panara MR ,Greco A , et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994;271:1705-1712
Web of Science | Medline24
FitzGerald GA ,Brash AR ,Falardeau P ,Oates JA . Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest 1981;68:1272-1275
CrossRef | Web of Science | Medline25
Sciulli MG, Patrignani P, Seta F, et al. Effects of acetaminophen on constitutive and inducible prostanoid biosynthesis in human blood cells in vitro. In: Proceedings of the 11th International Conference on Advances in Prostaglandin and Leukotriene Research: Basic Science and New Clinical Applications, Florence, Italy, June 4–8, 2000:38. abstract.
26
Reilly IAG ,FitzGerald GA . Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987;69:180-186
Web of Science | Medline27
McAdam BF ,Catella-Lawson F ,Mardini IA ,Kapoor S ,Lawson JA ,FitzGerald GA . Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999;96:272-277[Erratum, Proc Natl Acad Sci U S A 1999;96:5890.]
CrossRef | Web of Science | Medline28
Catella-Lawson F ,McAdam B ,Morrison BW , et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999;289:735-741
Web of Science | Medline29
Kaufman DW ,Kelly JP ,Sheehan JE , et al. Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding. Clin Pharmacol Ther 1993;53:485-494
CrossRef | Web of Science | Medline30
Hawkey C ,Laine L ,Simon T , et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2000;43:370-377
CrossRef | Web of Science | Medline31
Steering Committee of the Physicians' Health Study Research Group
Full Text | Web of Science | Medline32
The Medical Research Council's General Practice Research Framework
CrossRef | Web of Science | Medline33
Bombardier C ,Laine L ,Reicin A , et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-1528
Full Text | Web of Science | Medline34
Van Hecken A ,Schwartz JI ,Depre M , et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000;40:1109-1120
Web of Science | Medline35
Crofford LJ ,Oates JC ,McCune WJ , et al. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors: a report of four cases. Arthritis Rheum 2000;43:1891-1896
CrossRef | Web of Science | Medline36
Patrignani P ,Filabozzi P ,Patrono C . Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366-1372
CrossRef | Web of Science | Medline37
Pedersen AK ,FitzGerald GA . Dose-related kinetics of aspirin: presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984;311:1206-1211
Full Text | Web of Science | Medline38
Houtzager V ,Ouellet M ,Falgueyret JP ,Passmore LA ,Bayly C ,Percival MD . Inhibitor-induced changes in the intrinsic fluorescence of human cyclooxygenase-2. Biochemistry 1996;35:10974-10984
CrossRef | Web of Science | Medline39
Greig GM ,Francis DA ,Falgueyret JP , et al. The interaction of arginine 106 of human prostaglandin G/H synthase-2 with inhibitors is not a universal component of inhibition mediated by nonsteroidal anti-inflammatory drugs. Mol Pharmacol 1997;52:829-838
Web of Science | Medline40
Greenberg HE ,Gottesdiener K ,Huntington M , et al. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J Clin Pharmacol 2000;40:1509-1515
Web of Science | Medline41
Luong C ,Miller A ,Barnett J ,Chow J ,Ramesha C ,Browner MF . Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol 1996;3:927-933
CrossRef | Medline42
American College of Rheumatology Subcommittee on Osteoarthritis Guidelines
CrossRef | Web of Science | Medline43
Brune K . Prostaglandins and the mode of action of antipyretic analgesic drugs. Am J Med 1983;75:19-23
CrossRef | Web of Science | Medline44
Pincus T ,Koch GG ,Sokka T , et al. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 2001;44:1587-1598
CrossRef | Web of Science | Medline45
Rodriguez LA ,Hernandez-Diaz S . Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001;12:570-576
CrossRef | Web of Science | Medline
- Citing Articles (383)
Citing Articles
1
Giovanni Davì, Natale Vazzana, Simona Sestili. (2012) Variability in the response to antiplatelet treatment in diabetes mellitus. Prostaglandins & Other Lipid Mediators
CrossRef2
Wolfgang Lösche, Janina Boettel, Björn Kabisch, Johannes Winning, Ralf A. Claus, Michael Bauer. (2012) Do Aspirin and Other Antiplatelet Drugs Reduce the Mortality in Critically Ill Patients?. Thrombosis 2012, 1-8
CrossRef3
Bianca Rocca, Giovanna Petrucci. (2012) Variability in the Responsiveness to Low-Dose Aspirin: Pharmacological and Disease-Related Mechanisms. Thrombosis 2012, 1-11
CrossRef4
Philip G. Conaghan. (2011) A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatology International
CrossRef5
Femke Gijzen, Arie Knuistingh Neven. (2011) Ibuprofen remt werking acetylsalicylzuur. Huisarts en wetenschap
CrossRef6
Jeffrey K. Aronson. 2011. Adverse Drug Reactions: History, Terminology, Classification, Causality, Frequency, Preventability. , 1-119.
CrossRef7
M. Cattaneo. (2011) The Clinical Relevance of Response Variability to Antiplatelet Therapy. Hematology 2011:1, 70-75
CrossRef8
Gayle M. Halford, Marie Lordkipanidzé, Steve P. Watson. (2011) 50th anniversary of the discovery of ibuprofen: an interview with Dr Stewart Adams. Platelets1-8
CrossRef9
K. Awa, H. Satoh, S. Hori, Y. Sawada. (2011) Prediction of time-dependent interaction of aspirin with ibuprofen using a pharmacokinetic/pharmacodynamic model. Journal of Clinical Pharmacy and Therapeuticsno-no
CrossRef10
Dominick J. Angiolillo, Clara Hwang, Catherine Datto, Bhaloo Desai, Mark Sostek. (2011) Impact of a Fixed-Dose Combination of Naproxen and Esomeprazole Magnesium on Serum Thromboxane B2 Inhibition by Low-Dose Aspirin Over 5 Days in Healthy Adults: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Noninferiority Trial. Clinical Therapeutics
CrossRef11
Erasmia Broussalis, Monika Killer, Mark McCoy, Andrea Harrer, Eugen Trinka, Jörg Kraus. (2011) Current therapies in ischemic stroke. Part A. Recent developments in acute stroke treatment and in stroke prevention. Drug Discovery Today
CrossRef12
C. Patrono, F. Andreotti, H. Arnesen, L. Badimon, C. Baigent, J.-P. Collet, R. De Caterina, D. Gulba, K. Huber, S. Husted, S. D. Kristensen, J. Morais, F.-J. Neumann, L. H. Rasmussen, A. Siegbahn, P.-G. Steg, R. F. Storey, F. Van de Werf, F. Verheugt. (2011) Antiplatelet agents for the treatment and prevention of atherothrombosis. European Heart Journal
CrossRef13
Kadriye O. Kilickesmez, Cuneyt Kocas, Baris Okcun, Okay Abaci, Aysem Kaya, Alev Arat, Bilal Gorcin, Tevfik Gurmen. (2011) Laboratory signs of aspirin response in haemodialysis patients. Scandinavian Journal of Clinical & Laboratory Investigation 71:5, 426-431
CrossRef14
Paola Patrignani, Stefania Tacconelli, Annalisa Bruno, Carlos Sostres, Angel Lanas. (2011) Managing the adverse effects of nonsteroidal anti-inflammatory drugs. Expert Review of Clinical Pharmacology 4:5, 605-621
CrossRef15
Verónica Diez Diez, Ángeles Morales Martínez. (2011) Tratamiento antiagregante y cirugía. FMC - Formación Médica Continuada en Atención Primaria 18:7, 437-443
CrossRef16
Milo Engoren, Jonathan Hadaway, Thomas A. Schwann, Robert H. Habib. (2011) Ketorolac Improves Graft Patency After Coronary Artery Bypass Grafting: A Propensity-Matched Analysis. The Annals of Thoracic Surgery 92:2, 603-609
CrossRef17
V. Amoah, A. Smallwood, A.P. Worrall, T. Lovatt, A.L. Armesilla, A.M. Nevill, J.M. Cotton. (2011) Poor aspirin response in diabetic patients presenting with acute coronary syndromes: Results using a near patient test. Thrombosis Research 128:2, 196-199
CrossRef18
Samuel Yip, Oscar Benavente. (2011) Antiplatelet Agents for Stroke Prevention. Neurotherapeutics 8:3, 475-487
CrossRef19
Anthony A. Bavry, Asma Khaliq, Yan Gong, Eileen M. Handberg, Rhonda M. Cooper-DeHoff, Carl J. Pepine. (2011) Harmful Effects of NSAIDs among Patients with Hypertension and Coronary Artery Disease. The American Journal of Medicine 124:7, 614-620
CrossRef20
Virginia A. Pujol Lereis, Sebastian Ameriso, Guillermo P. Povedano, Sebastián F. Ameriso. (2011) Ischemic Stroke in Patients Receiving Aspirin. Journal of Stroke and Cerebrovascular Diseases
CrossRef21
Olivier Barthélémy, Tobias Limbourg, Jean Philippe Collet, Farzin Beygui, Johanne Silvain, Anne Bellemain-Appaix, Guillaume Cayla, Thomas Chastre, Iris Baumgartner, Joachim Röther, Uwe Zeymer, Deepak L. Bhatt, Gabriel Steg, Gilles Montalescot. (2011) Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors. International Journal of Cardiology
CrossRef22
Antonio Tello-Montoliu, Masafumi Ueno, Dominick J Angiolillo. (2011) Antiplatelet drug therapy: role of pharmacodynamic and genetic testing. Future Cardiology 7:3, 381-402
CrossRef23
Richard FitzGerald, Munir Pirmohamed. (2011) Aspirin resistance: Effect of clinical, biochemical and genetic factors. Pharmacology & Therapeutics 130:2, 213-225
CrossRef24
M. Oberhänsli, S. Puricel, M. Togni, S. Cook. (2011) Koronare Stent-Thrombosen. Herz 36:3, 241-253
CrossRef25
Alan D. Bell, André Roussin, Raymond Cartier, Wee Shian Chan, James D. Douketis, Anil Gupta, Maria E. Kraw, Thomas F. Lindsay, Michael P. Love, Neesh Pannu, Rémi Rabasa-Lhoret, Ashfaq Shuaib, Philip Teal, Pierre Théroux, Alexander G.G. Turpie, Robert C. Welsh, Jean-François Tanguay. (2011) The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines. Canadian Journal of Cardiology 27:3, S1-S59
CrossRef26
Stefano Fiorucci, Andrea Mencarelli, Sabrina Cipriani, Barbara Renga, Giuseppe Palladino, Luca Santucci, Eleonora Distrutti. (2011) Activation of the Bile Acid Sensor FXR Protects Against Gastrointestinal Injury Caused By ASA And NSAIDs in Mice. British Journal of Pharmacologyno-no
CrossRef27
Monika Killer, Eugen Trinka, Jörg Kraus, Erasmia Broussalis. (2011) Discovery, development and effectiveness of coagulation-inhibiting drugs for stroke therapy. Expert Opinion on Drug Discovery 6:4, 353-369
CrossRef28
Paola Anzellotti, Marta L. Capone, Anita Jeyam, Stefania Tacconelli, Annalisa Bruno, Paola Tontodonati, Luigia Di Francesco, Linda Grossi, Giulia Renda, Gabriele Merciaro, Patrizia Di Gregorio, Thomas S. Price, Luis A. Garcia Rodriguez, Paola Patrignani. (2011) Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: Recommendations to minimize the functional consequences. Arthritis & Rheumatism 63:3, 850-859
CrossRef29
Daniel E Becker. (2011) Adverse Drug Interactions. Anesthesia Progress 58:1, 31-41
CrossRef30
Zhi-Gang Guo, Yun Liu, Xin-Hui Xing. (2011) Enhanced catharanthine biosynthesis through regulation of cyclooxygenase in the cell suspension culture of Catharanthus roseus (L.) G. Don. Process Biochemistry 46:3, 783-787
CrossRef31
Alan D. Bell, André Roussin, Raymond Cartier, Wee Shian Chan, James D. Douketis, Anil Gupta, Maria E. Kraw, Thomas F. Lindsay, Michael P. Love, Neesh Pannu, Rémi Rabasa-Lhoret, Ashfaq Shuaib, Philip Teal, Pierre Théroux, A. Graham Turpie, Robert C. Welsh, Jean-François Tanguay. (2011) The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines Executive Summary. Canadian Journal of Cardiology 27:2, 208-221
CrossRef32
K. M. MUSALLAM, K. CHARAFEDDINE, A. BITAR, M. KHOURY, S. ASSAAD, J. BERESIAN, S. ALAM, A. T. TAHER. (2011) Resistance to aspirin and clopidogrel therapy. International Journal of Laboratory Hematology 33:1, 1-18
CrossRef33
Richard Hall, C. David Mazer. (2011) Antiplatelet Drugs. Anesthesia & Analgesia 112:2, 292-318
CrossRef34
Mehmet Akif Topçuoglu, Ethem Murat Arsava, Hakan Ay. (2011) Antiplatelet resistance in stroke. Expert Review of Neurotherapeutics 11:2, 251-263
CrossRef35
Toshiyuki Sakata, Kazuomi Kario. (2011) Antiplatelet therapy effectively reduces plasma plasminogen activator inhibitor-1 levels. Atherosclerosis 214:2, 490-491
CrossRef36
Robert P. Sundel, Ross E. Petty. 2011. KAWASAKI DISEASE. , 505-520.
CrossRef37
H. Pieringer, M. Pichler. (2011) Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications. QJM 104:1, 13-26
CrossRef38
Naoko ITO, Haruko YOKOYAMA, Shinji SOEDA, Yuji SUZUKI, Noriyuki IKEDA, Kentaro TOKUOKA, Masayuki WATANABE, Yasuhisa KITAGAWA, Yasuhiko YAMADA. (2011) Investigation into the Combination of Aspirin with Non-steroidal Anti-inflammatory Drugs. YAKUGAKU ZASSHI 131:7, 1073-1077
CrossRef39
Hironori NAKAMURA, Haruko YOKOYAMA, Takehiro YAGUCHI, Yuji SUZUKI, Kentaro TOKUOKA, Masayuki WATANABE, Yasuhisa KITAGAWA, Yasuhiko YAMADA. (2011) Investigation into the Effect of Gastric Secretion Inhibitor for the Prevention of Upper Gastrointestinal Lesions Associated with Low-dose Aspirin. YAKUGAKU ZASSHI 131:3, 445-452
CrossRef40
Yuuki Akagi, Yuta Nio, Shuji Shimada, Takao Aoyama. (2011) Influence of Nonsteroidal Anti-inflammatory Drugs on the Antiplatelet Effects of Aspirin in Rats. Biological & Pharmaceutical Bulletin 34:2, 233-237
CrossRef41
Mar Castellanos, Babette B. Weksler, Oscar R. Benavente. 2011. Antiplatelet Therapy for Secondary Prevention of Stroke. , 1147-1172.
CrossRef42
Wiebke Gogarten, Erik Vandermeulen, Hugo Van Aken, Sibylle Kozek, Juan V Llau, Charles M Samama. (2010) Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. European Journal of Anaesthesiology 27:12, 999-1015
CrossRef43
L. Drouet, C. Bal dit Sollier, P. Henry. (2010) Antiagrégants plaquettaires et diabète. Annales de Cardiologie et d'Angéiologie 59, S56-S64
CrossRef44
David M. Greer. (2010) Aspirin and Antiplatelet Agent Resistance. CNS Drugs 24:12, 1027-1040
CrossRef45
Mino Kang, SeongSoo A. An. (2010) Acetaminophen and its regioisomer, 3-acetamidophenol interfered with the growth ofEscherichia coli O157:H7. Toxicology and Environmental Health Sciences 2:4, 278-283
CrossRef46
Jochen Börgermann, Alena Kanashnik, Maik Sossdorf, Jan Gummert, Wolfgang Lösche. (2010) Individual variability of response and non-response to acetyl salicylic acid after cardiac surgery. Platelets 21:8, 610-615
CrossRef47
I. S. Mackenzie, M. W. H. Coughtrie, T. M. MacDonald, L. Wei. (2010) Antiplatelet drug interactions. Journal of Internal Medicine 268:6, 516-529
CrossRef48
H. S. Kirshner. (2010) Current issues in antiplatelet therapy for stroke prevention: the importance of stroke subtypes and differences between stroke and MI patients. Journal of Neurology 257:11, 1788-1797
CrossRef49
Jean-Luc Reny, Robert F. Bonvini, John M. Bonvini, Marco Roffi, Pierre Fontana. (2010) Poor Responsiveness to Antiplatelet Drugs in Acute Coronary Syndromes: Clinical Relevance and Management. Cardiovascular Therapeuticsno-no
CrossRef50
K. Brune. (2010) Kardiovaskuläre Komplikationen unter Zyklooxygenasehemmern. Zeitschrift für Rheumatologie 69:8, 712-718
CrossRef51
Kay Brune, Bertold Renner, Burkhard Hinz. (2010) Using pharmacokinetic principles to optimize pain therapy. Nature Reviews Rheumatology 6:10, 589-598
CrossRef52
Samuel Chackalamannil. 2010. Antiplatelet Agents. .
CrossRef53
Alaa Rostom, Katherine Muir, Catherine Dubé, Emilie Jolicoeur, Michel Boucher, Peter Tugwell, George Wells. 2010. Non-Steroidal Anti-Inflammatory Drug-Induced Gastro-Duodenal Toxicity. , 139-164.
CrossRef54
Elisabeth Mahla, Helfried Metzler, Udaya S. Tantry, Paul A. Gurbel. (2010) Controversies in Oral Antiplatelet Therapy in Patients Undergoing Aortocoronary Bypass Surgery. The Annals of Thoracic Surgery 90:3, 1040-1051
CrossRef55
Vincent E. Friedewald, Joel S. Bennett, J. Paul Christo, James L. Pool, James M. Scheiman, Lee S. Simon, Vibeke Strand, William B. White, Gary W. Williams, William C. Roberts. (2010) AJC Editor's Consensus: Selective and Nonselective Nonsteroidal Anti-Inflammatory Drugs and Cardiovascular Risk. The American Journal of Cardiology 106:6, 873-884
CrossRef56
Beste Ozben, Azra M. Tanrikulu, Tomris Ozben, Oguz Caymaz. (2010) Aspirin Resistance in Hypertensive Patients. The Journal of Clinical Hypertension 12:9, 714-720
CrossRef57
Kumaran Kolandaivelu, Deepak L. Bhatt. (2010) Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence. Nature Reviews Cardiology 7:8, 461-467
CrossRef58
Muhammad Amer, Valeriani R. Bead, Joan Bathon, Roger S. Blumenthal, David N. Edwards. (2010) Use of Nonsteroidal Anti-Inflammatory Drugs in Patients With Cardiovascular Disease. Cardiology in Review 18:4, 204-212
CrossRef59
John Oldenhof, Marc Hochberg, Michael Schiff, Kay Brune. (2010) Effect of maximum OTC doses of naproxen sodium or acetaminophen on low-dose aspirin inhibition of serum thromboxane B 2. Current Medical Research and Opinion 26:6, 1497-1504
CrossRef60
J. W. Chu, C. K. Wong, J. Chambers, J. V. Wout, P. Herbison, E. W. Tang. (2010) Aspirin resistance determined from a bed-side test in patients suspected to have acute coronary syndrome portends a worse 6 months outcome. QJM 103:6, 405-412
CrossRef61
Fernando D. Testai, Philip B. Gorelick. (2010) New Approaches to Stroke Prevention in Atrial Fibrillation. Current Treatment Options in Cardiovascular Medicine 12:3, 261-273
CrossRef62
Lakshmi Pillai, Robert M. Levy, Mesfin Yimam, Yuan Zhao, Qi Jia, Bruce P. Burnett. (2010) Flavocoxid, an anti-inflammatory agent of botanical origin, does not affect coagulation or interact with anticoagulation therapies. Advances in Therapy 27:6, 400-411
CrossRef63
Daniel E. Becker. (2010) Pain Management: Part 1: Managing Acute and Postoperative Dental Pain. Anesthesia Progress 57:2, 67-79
CrossRef64
Neal S. Kleiman. (2010) Resistance or resistors? Has Ohm's law come to antiplatelet therapy?. American Heart Journal 159:5, 713-715
CrossRef65
Charles H. Hennekens, Wendy R. Schneider, Patricia R. Hebert, Udaya S. Tantry, Paul A. Gurbel. (2010) Hypothesis formulation from subgroup analyses: Nonadherence or nonsteroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to “aspirin resistance”. American Heart Journal 159:5, 744-748
CrossRef66
R. Ward. (2010) Identifying and assessing benefit-risk in primary care--a family physician's perspective. Rheumatology 49:Supplement 2, ii18-ii23
CrossRef67
Antonio González-Pérez, Luis Alberto García Rodriguez. 2010. Cardiovascular Toxicities of NSAIDS: Epidemiologic Aspects. , 287-312.
CrossRef68
James M. Scheiman, Clemence E. Hindley. (2010) Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clinical Therapeutics 32:4, 667-677
CrossRef69
N. Müller. (2010) Medikamentöse Schmerztherapie bei osteoporotischen Frakturen und deren Folgezuständen. Der Orthopäde 39:4, 371-379
CrossRef70
Emer M Smyth. (2010) Thromboxane and the thromboxane receptor in cardiovascular disease. Clinical Lipidology 5:2, 209-219
CrossRef71
Graeme J Hankey, John W Eikelboom. (2010) Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. The Lancet Neurology 9:3, 273-284
CrossRef72
Rahul Sakhuja, Robert W. Yeh, Deepak L. Bhatt. (2010) Antiplatelet Agents in Acute Coronary Syndromes. Current Problems in Cardiology 35:3, 123-170
CrossRef73
R.C. Block, R. Duff, P. Lawrence, L. Kakinami, J.T. Brenna, G.C. Shearer, N. Meednu, S. Mousa, A. Friedman, W.S. Harris, Mark Larson, S. Georas. (2010) The Effects of EPA, DHA, and Aspirin Ingestion on Plasma Lysophospholipids and Autotaxin. Prostaglandins, Leukotrienes and Essential Fatty Acids 82:2-3, 87-95
CrossRef74
Carlo Patrono, Bianca Rocca. (2010) The Future of Antiplatelet Therapy in Cardiovascular Disease. Annual Review of Medicine 61:1, 49-61
CrossRef75
Harald E. Vonkeman, Mart A.F.J. van de Laar. (2010) Nonsteroidal Anti-Inflammatory Drugs: Adverse Effects and Their Prevention. Seminars in Arthritis and Rheumatism 39:4, 294-312
CrossRef76
G. Rimon, R. S. Sidhu, D. A. Lauver, J. Y. Lee, N. P. Sharma, C. Yuan, R. A. Frieler, R. C. Trievel, B. R. Lucchesi, W. L. Smith. (2010) Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1. Proceedings of the National Academy of Sciences 107:1, 28-33
CrossRef77
Jane Newburger. 2010. Kawasaki Disease. , 1067-1078.
CrossRef78
Rolando E. Rumbaut, Perumal Thiagarajan. (2010) Platelet-Vessel Wall Interactions in Hemostasis and Thrombosis. Colloquium Series on Integrated Systems Physiology: From Molecule to Function 2:1, 1-75
CrossRef79
Robin E. Ferner, Jeffrey K. Aronson. (2010) EIDOS. Drug Safety 33:1, 15-23
CrossRef80
K. D. Rainsford. (2009) Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology 17:6, 275-342
CrossRef81
A. M. Cerbone, N. Macarone-Palmieri, G. Saldalamacchia, A. Coppola, G. Di Minno, A. A. Rivellese. (2009) Diabetes, vascular complications and antiplatelet therapy: open problems. Acta Diabetologica 46:4, 253-261
CrossRef82
Silvio Caccia, Silvio Garattini, Luca Pasina, Alessandro Nobili. (2009) Predicting the Clinical Relevance of Drug Interactions From Pre-Approval Studies. Drug Safety 32:11, 1017-1039
CrossRef83
Deepak Thomas, Robert P. Giugliano. (2009) Management of ST-segment elevation myocardial infarction: Comparison of the updated guidelines from North America and Europe. American Heart Journal 158:5, 695-705
CrossRef84
Birgit Linnemann, Stephanie Prochnow, Helen Mani, Jan Schwonberg, Edelgard Lindhoff-Last. (2009) Variability of non-response to aspirin in patients with peripheral arterial occlusive disease during long-term follow-up. Annals of Hematology 88:10, 979-988
CrossRef85
Francisco Marín, Rocío González-Conejero, Piera Capranzano, Theodore A. Bass, Vanessa Roldán, Dominick J. Angiolillo. (2009) Pharmacogenetics in Cardiovascular Antithrombotic Therapy. Journal of the American College of Cardiology 54:12, 1041-1057
CrossRef86
Udaya S. Tantry, Elisabeth Mahla, Paul A. Gurbel. (2009) Aspirin Resistance. Progress in Cardiovascular Diseases 52:2, 141-152
CrossRef87
Angel Lanas. (2009) Nonsteroidal Antiinflammatory Drugs and Cyclooxygenase Inhibition in the Gastrointestinal Tract: A Trip From Peptic Ulcer to Colon Cancer. The American Journal of the Medical Sciences 338:2, 96-106
CrossRef88
MP Schuijt, HWHA Huntjens-Fleuren, M de Metz, EJ Vollaard. (2009) The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers. British Journal of Pharmacology 157:6, 931-934
CrossRef89
Emile R. Mohler. (2009) Combination antiplatelet therapy in patients with peripheral arterial disease: Is the best therapy aspirin, clopidogrel, or both?. Catheterization and Cardiovascular Interventions 74:S1, S1-S6
CrossRef90
Itsik Ben-Dor, Neal S. Kleiman, Eli Lev. (2009) Assessment, Mechanisms, and Clinical Implication of Variability in Platelet Response to Aspirin and Clopidogrel Therapy. The American Journal of Cardiology 104:2, 227-233
CrossRef91
Gunnar H Gislason, Peter R Hansen. (2009) NSAIDs in elderly patients with heart failure: stuck between a rock and a hard place?. Aging Health 5:3, 259-262
CrossRef92
S. Shakib. (2009) Aspirin for primary prevention: do potential benefits outweigh the risks?. Internal Medicine Journal 39:6, 401-407
CrossRef93
James M. Scheiman. (2009) Balancing Risks and Benefits of Cyclooxygenase-2 Selective Nonsteroidal Anti-Inflammatory Drugs. Gastroenterology Clinics of North America 38:2, 305-314
CrossRef94
Michael E. Farkouh, Bruce P. Greenberg. (2009) An Evidence-Based Review of the Cardiovascular Risks of Nonsteroidal Anti-Inflammatory Drugs. The American Journal of Cardiology 103:9, 1227-1237
CrossRef95
Katja S. Galliard-Grigioni, Walter H. Reinhart. (2009) A randomized, controlled study on the influence of acetaminophen, diclofenac, or naproxen on aspirin-induced inhibition of platelet aggregation. European Journal of Pharmacology 609:1-3, 96-99
CrossRef96
Allison G. Dupont, Don A. Gabriel, Mauricio G. Cohen. (2009) Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome. Thrombosis Research 124:1, 6-13
CrossRef97
Sofie S. Hedegaard, Anne-Mette Hvas, Erik L. Grove, Jens Refsgaard, Bianca Rocca, Giovanni Daví, Steen D. Kristensen. (2009) Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration. Thrombosis Research 124:1, 96-100
CrossRef98
Joseph M. Sweeny, Diana A. Gorog, Valentin Fuster. (2009) Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. Nature Reviews Cardiology 6:4, 273-282
CrossRef99
David P. Faxon, Jane E. Freedman. (2009) Facts and controversies of aspirin and clopidogrel therapy. American Heart Journal 157:3, 412-422
CrossRef100
Gilead I. Lancaster, Janardhan Srinivasan, Hitender Jain. (2009) Aspirin resistance: An update. Current Atherosclerosis Reports 11:2, 105-110
CrossRef101
Tomoko Mori, Takuya Kubo, Kunimitsu Kaya, Ken Hosoya. (2009) Importance of surface properties of affinity resin for capturing a target protein, Cyclooxygenase-1. Bioorganic & Medicinal Chemistry 17:4, 1587-1599
CrossRef102
Matthias Hermann. (2009) Cardiovascular risk associated with nonsteroidal anti-inflammatory drugs. Current Rheumatology Reports 11:1, 31-35
CrossRef103
Victor L. Serebruany, Christian Eisert, Dan Atar, James J. Ferguson. (2009) Antiplatelet ‘resistance’ and ‘non-responders’: what do these terms really mean?. Fundamental & Clinical Pharmacology 23:1, 11-18
CrossRef104
Francesca Santilli, Bianca Rocca, Raimondo De Cristofaro, Stefano Lattanzio, Laura Pietrangelo, Aida Habib, Caterina Pettinella, Antonio Recchiuti, Elisabetta Ferrante, Giovanni Ciabattoni, Giovanni Davì, Carlo Patrono. (2009) Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays. Journal of the American College of Cardiology 53:8, 667-677
CrossRef105
Farhan Majeed, Willem J Kop, Robert S Poston, Seeta Kallam, Mandeep R Mehra. (2009) Prospective, observational study of antiplatelet and coagulation biomarkers as predictors of thromboembolic events after implantation of ventricular assist devices. Nature Clinical Practice Cardiovascular Medicine 6:2, 147-157
CrossRef106
Tae-gyu Nam, Susheel J. Nara, Irène Zagol-Ikapitte, Thomas Cooper, Luca Valgimigli, John A. Oates, Ned A. Porter, Olivier Boutaud, Derek A. Pratt. (2009) Pyridine and pyrimidine analogs of acetaminophen as inhibitors of lipid peroxidation and cyclooxygenase and lipoxygenase catalysis. Organic & Biomolecular Chemistry 7:24, 5103
CrossRef107
Cheryl D. Bushnell, Cathleen S. Colón-Emeric. (2009) Secondary Stroke Prevention Strategies for the Oldest Patients. Drugs & Aging 26:3, 209-230
CrossRef108
Dominick J. Angiolillo, Siva Suryadevara, Piera Capranzano, Martin Z. Zenni, Luis A. Guzman, Theodore A. Bass. (2009) Antiplatelet drug response variability and the role of platelet function testing: A practical guide for interventional cardiologists. Catheterization and Cardiovascular Interventions 73:1, 1-14
CrossRef109
Seung-woon Keum, Yeon-kyun Oh, Jong-duck Kim, Seung-taek Yu. (2009) Comparison and analysis of the effectiveness to high dose of aspirin and ibuprofen in acute phase of Kawasaki disease. Korean Journal of Pediatrics 52:8, 930
CrossRef110
Michael B. Soyka, Kaspar Rufibach, Alex Huber, David Holzmann. (2009) Is severe epistaxis associated with acetylsalicylic acid intake?. The LaryngoscopeNA-NA
CrossRef111
Khaled Mansour, Ali T. Taher, Khaled M. Musallam, Samir Alam. (2009) Aspirin Resistance. Advances in Hematology 2009, 1-10
CrossRef112
Sarah McClelland, Meinrad Gawaz, Elisabeth Kennerknecht, Carolin Sophie Ildiko Konrad, Susanne Sauer, Katrin Schuerzinger, Steffen Massberg, Desmond J. Fitzgerald, Orina Belton. (2009) Contribution of cyclooxygenase-1 to thromboxane formation, platelet–vessel wall interactions and atherosclerosis in the ApoE null mouse. Atherosclerosis 202:1, 84-91
CrossRef113
Young Sang Kim, Kyoung Kon Kim, In Cheol Hwang. (2009) Aspirin Usage Based on Evidence for the Prevention of Cardio-Cerebrovascular Disease. Korean Journal of Family Medicine 30:4, 249
CrossRef114
C. Michael Gibson, Yuri B. Pride, Philip E. Aylward, Jacques J. Col, Shaun G. Goodman, Dietrich Gulba, Mijo Bergovec, Vijayalakshmi Kunadian, Cafer Zorkun, Jacqueline L. Buros, Sabina A. Murphy, Elliott M. Antman. (2009) Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis. Journal of Thrombosis and Thrombolysis 27:1, 11-17
CrossRef115
Barry Schlansky, Joo Ha Hwang. (2009) Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy. Journal of Gastroenterology 44:S19, 44-52
CrossRef116
Loren Laine, William B. White, Alaa Rostom, Marc Hochberg. (2008) COX-2 Selective Inhibitors in the Treatment of Osteoarthritis. Seminars in Arthritis and Rheumatism 38:3, 165-187
CrossRef117
Arthur L Weaver. (2008) Current and Emerging Treatments for Mild/Moderate Acute Ambulatory Pain. American Journal of Therapeutics 15:Supplement 10, S12-S16
CrossRef118
Neal S. Kleiman. (2008) Clopidogrel and Calcium-Channel Antagonists. Journal of the American College of Cardiology 52:19, 1564-1566
CrossRef119
N. ELNACHEF, J. M. SCHEIMAN, A. M. FENDRICK, C. W. HOWDEN, W. D. CHEY. (2008) Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providers. Alimentary Pharmacology & Therapeutics 28:10, 1249-1258
CrossRef120
Loren Laine, Sean P. Curtis, Michael Langman, Dennis M. Jensen, Byron Cryer, Amarjot Kaur, Christopher P. Cannon. (2008) Lower Gastrointestinal Events in a Double-Blind Trial of the Cyclo-Oxygenase-2 Selective Inhibitor Etoricoxib and the Traditional Nonsteroidal Anti-Inflammatory Drug Diclofenac. Gastroenterology 135:5, 1517-1525
CrossRef121
E. Paresce, A. Murgo, L. Pisoni, O. Lucia, E. Schito, E. Valcamonica, A. Celant, A. Ferrara, D. Comi. (2008) La terapia farmacologica delle ernie discali. Archivio di Ortopedia e Reumatologia 119:2, 10-12
CrossRef122
Luis Alberto García Rodríguez, Stefania Tacconelli, Paola Patrignani. (2008) Role of Dose Potency in the Prediction of Risk of Myocardial Infarction Associated With Nonsteroidal Anti-Inflammatory Drugs in the General Population. Journal of the American College of Cardiology 52:20, 1628-1636
CrossRef123
T.-P. van Staa, S. Rietbrock, E. Setakis, H. G. M. Leufkens. (2008) Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?. Journal of Internal Medicine 264:5, 481-492
CrossRef124
W. Jaksch, C. Dejaco, M. Schirmer. (2008) 4 years after withdrawal of rofecoxib: where do we stand today?. Rheumatology International 28:12, 1187-1195
CrossRef125
Katja S. Galliard-Grigioni, Martin Fehr, Walter H. Reinhart. (2008) Influence of combinations of acetylsalicylic acid, acetaminophen, and diclofenac on platelet aggregation. European Journal of Pharmacology 595:1-3, 65-68
CrossRef126
Lei Fang, Jochen Lehmann. (2008) NO donor hybrid compounds as multifunctional therapeutic agents. Expert Opinion on Therapeutic Patents 18:10, 1111-1125
CrossRef127
W. Kuliczkowski, A. Witkowski, L. Polonski, C. Watala, K. Filipiak, A. Budaj, J. Golanski, D. Sitkiewicz, J. Pregowski, J. Gorski, M. Zembala, G. Opolski, K. Huber, H. Arnesen, S. D. Kristensen, R. De Caterina. (2008) Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. European Heart Journal 30:4, 426-435
CrossRef128
Angela G. Juby, Paul Davis. (2008) Utility of published guidelines on the use of nonsteroidal anti-inflammatory drugs in the elderly. Clinical Rheumatology 27:9, 1191-1194
CrossRef129
José Biller. (2008) Aspirin nonresponse in patients with arterial causes of ischemic stroke: Considerations in detection and management. Journal of the Neurological Sciences 272:1-2, 1-7
CrossRef130
Daniel H. Solomon, Robert J. Glynn, Kenneth J. Rothman, Sebastian Schneeweiss, Soko Setoguchi, Helen Mogun, Jerry Avorn, Til Stürmer. (2008) Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis & Rheumatism 59:8, 1097-1104
CrossRef131
Lisa T. Newsome, Robert S. Weller, J C. Gerancher, Michael A. Kutcher, Roger L. Royster. (2008) Coronary Artery Stents: II. Perioperative Considerations and Management. Anesthesia & Analgesia 107:2, 570-590
CrossRef132
Burkhard Hinz, Kay Brune. (2008) Can drug removals involving cyclooxygenase-2 inhibitors be avoided? A plea for human pharmacology. Trends in Pharmacological Sciences 29:8, 391-397
CrossRef133
Anita Airee, Heather M Draper, Shannon W Finks. (2008) Aspirin Resistance: Disparities and Clinical Implications. Pharmacotherapy 28:8, 999-1018
CrossRef134
Norbert Zimmermann, Emmeran Gams, Thomas Hohlfeld. (2008) Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent. European Journal of Cardio-Thoracic Surgery 34:1, 93-108
CrossRef135
Javier de Teresa Galván. (2008) Aproximación B. Evidencia de prescripción de un antiinflamatorio no esteroideo tradicional asociado a inhibidor de la bomba de protones en un paciente al que se le administra aspirina como prevención cardiovascular. Gastroenterología y Hepatología 31, 42-44
CrossRef136
R van Westrhenen, CC Gispen-de Wied, JFF Lekkerkerker. (2008) Blunting of the Cardiovascular Effect of Aspirin by Ibuprofen: What Is the Evidence?. Clinical Pharmacology & Therapeutics 83:6, 812-812
CrossRef137
P Patrignani, G Renda, S Tacconelli, ML Capone, D Sacchetta, F Santarelli, MG Sciulli, M Zimarino, M Grana, E D’Amelio, M Zurro, C Patrono, R De Caterina. (2008) Response to “Pharmacodynamic Interaction Between Aspirin and Ibuprofen: A Plausible Mechanism of Aspirin Resistance”. Clinical Pharmacology & Therapeutics 83:6, 812-813
CrossRef138
Gayle McKellar, Rajan Madhok, Gurkirpal Singh. (2008) Update on the use of analgesics versus nonsteroidal anti-inflammatory drugs in rheumatic disorders: risks and benefits. Current Opinion in Rheumatology 20:3, 239-245
CrossRef139
Deepak Thomas, Robert P Giugliano. (2008) Antiplatelet Therapy in Early Management of Non-ST-segment Elevation Acute Coronary Syndrome: The 2002 and 2007 Guidelines From North America and Europe. Journal of Cardiovascular Pharmacology 51:5, 425-433
CrossRef140
Kena Lanham, Kelly Smith, Jeremy Flynn. (2008) Considering Cardiovascular Risks when Using NSAIDs. Orthopedics 31:5, 468-471
CrossRef141
Simon J Read, Andy Dray. (2008) Osteoarthritic pain: a review of current, theoretical and emerging therapeutics. Expert Opinion on Investigational Drugs 17:5, 619-640
CrossRef142
Anthony Sebba. (2008) Efficacy and safety of etoricoxib in the treatment of osteoarthritis. Expert Review of Clinical Pharmacology 1:3, 345-355
CrossRef143
C. J. Hawkey. (2008) Safer NSAID strategies: consensus or contentious?. Rheumatology 47:9, 1265-1266
CrossRef144
V. F. Panoulas, G. S. Metsios, A. V. Pace, H. John, G. J. Treharne, M. J. Banks, G. D. Kitas. (2008) Hypertension in rheumatoid arthritis. Rheumatology 47:9, 1286-1298
CrossRef145
Patrick A. Gladding, Mark W.I. Webster, Helen B. Farrell, Irene S.L. Zeng, Robert Park, Nicola Ruijne. (2008) The Antiplatelet Effect of Six Non-Steroidal Anti-Inflammatory Drugs and Their Pharmacodynamic Interaction With Aspirin in Healthy Volunteers. The American Journal of Cardiology 101:7, 1060-1063
CrossRef146
J. Jage, R. Laufenberg-Feldmann, F. Heid. (2008) Medikamente zur postoperativen Schmerztherapie: Bewährtes und Neues. Der Anaesthesist 57:4, 382-390
CrossRef147
David Y. Graham, Francis K.L. Chan. (2008) NSAIDs, Risks, and Gastroprotective Strategies: Current Status and Future. Gastroenterology 134:4, 1240-1246
CrossRef148
Steven B Abramson, Jeffrey D Greenberg. (2008) Are NSAIDs and selective cyclo-oxygenase 2 inhibitors associated with increased risk of myocardial infarction?. Nature Clinical Practice Rheumatology 4:4, 182-183
CrossRef149
Elham Rahme, Alan Barkun, Hacene Nedjar, Sabine Gaugris, Douglas Watson. (2008) Hospitalizations for Upper and Lower GI Events Associated With Traditional NSAIDs and Acetaminophen Among the Elderly in Quebec, Canada. The American Journal of Gastroenterology 103:4, 872-882
CrossRef150
Patrick Gladding, Mark Webster, John Ormiston, Sarah Olsen, Harvey White. (2008) Antiplatelet drug nonresponsiveness. American Heart Journal 155:4, 591-599
CrossRef151
Yu-Min Yang, Jun-Zhu Chen, Xing-Xiang Wang, Shi-Jun Wang, Hu Hu, Hong-Qiang Wang. (2008) Resveratrol attenuates thromboxane A2 receptor agonist-induced platelet activation by reducing phospholipase C activity. European Journal of Pharmacology 583:1, 148-155
CrossRef152
Debabrata Mukherjee. (2008) Nonsteroidal Anti-Inflammatory Drugs and the Heart: What Is the Danger?. Congestive Heart Failure 14:2, 75-82
CrossRef153
Eugene Braunwald, Dominick Angiolillo, Eric Bates, Peter B. Berger, Deepak Bhatt, Christopher P. Cannon, Mark I. Furman, Paul Gurbel, Alan D. Michelson, Eric Peterson, Stephen Wiviott. (2008) Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches. Clinical Cardiology 31:S1, I21-I27
CrossRef154
James W. Hoekstra. (2008) Rules of engagement: The hospitalist and atherothrombosis. Journal of Hospital Medicine 3:S2, S1-S3
CrossRef155
Cliff K. S. Ong, Robin A. Seymour. (2008) An evidence-based update of the use of analgesics in dentistry. Periodontology 2000 46:1, 143-164
CrossRef156
Carla R. Scanzello, Neal K. Moskowitz, Allan Gibofsky. (2008) The Post-NSAID Era: What to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis. Current Rheumatology Reports 10:1, 49-56
CrossRef157
James M Brophy. (2008) Cardiovascular effects of cyclooxygenase-2 inhibitors. Current Opinion in Internal Medicine 7:1, 29-36
CrossRef158
Elliot V. Hersh, Paul A. Moore. (2008) Adverse drug interactions in dentistry. Periodontology 2000 46:1, 109-142
CrossRef159
Denis Wahl, Thomas Lecompte, Henri Bounameaux. (2008) Need for additional trials of primary prophylaxis in patients with high-risk antiphospholipid antibody profiles: Comment on the article by Erkan et al. Arthritis & Rheumatism 58:2, 635-636
CrossRef160
T. HOHLFELD, N. ZIMMERMANN, A.-A. WEBER, G. JESSEN, H. WEBER, K. SCHRÖR, H. -D. HÖLTJE, R. EBEL. (2008) Pyrazolinone analgesics prevent the antiplatelet effect of aspirin and preserve human platelet thromboxane synthesis1. Journal of Thrombosis and Haemostasis 6:1, 166-173
CrossRef161
Francis KL Chan. (2008) The David Y. Graham Lecture: Use of Nonsteroidal Antiinflammatory Drugs in a COX-2 Restricted Environment. The American Journal of Gastroenterology 103:1, 221-227
CrossRef162
Silvia Riondino, Elisabetta Trifirò, Lorenzo Principessa, Silvia Mascioletti, Livia Di Renzo, Carlo Gaudio, Luigi M. Biasucci, Filippo Crea, Fabio M. Pulcinelli. (2008) Lack of biological relevance of platelet cyclooxygenase-2 dependent thromboxane A2 production. Thrombosis Research 122:3, 359-365
CrossRef163
Tahir Durmaz, Telat Keles, Ozcan Ozdemir, Nihal Akar Bayram, Murat Akcay, Ekrem Yeter, Engin Bozkurt. (2008) Heart Rate Variability in Patients With Stable Coronary Artery Disease and Aspirin Resistance. International Heart Journal 49:4, 413-422
CrossRef164
Steven R. Steinhubl, Jennifer J. Oh, Julie H. Oestreich, Suellen Ferraris, Richard Charnigo, Wendell S. Akers. (2008) Transitioning patients from cangrelor to clopidogrel: Pharmacodynamic evidence of a competitive effect. Thrombosis Research 121:4, 527-534
CrossRef165
Asokumar Buvanendran, Scott S. Reuben. 2008. Nonsteroidal Anti-inflammatory Drugs, Acetaminophen, and COX-2 Inhibitors. , 671-692.
CrossRef166
Ying Hong, Fran M Gengo, Michelle M Rainka, Vernice E Bates, Donald E Mager. (2008) Population Pharmacodynamic Modelling of Aspirin- and Ibuprofen-Induced Inhibition of Platelet Aggregation in Healthy Subjects. Clinical Pharmacokinetics 47:2, 129-137
CrossRef167
Sejung Sohn, Kihwan Kwon. (2008) Accelerated Thrombotic Occlusion of a Medium-Sized Coronary Aneurysm in Kawasaki Disease by the Inhibitory Effect of Ibuprofen on Aspirin. Pediatric Cardiology 29:1, 153-156
CrossRef168
Carmen S. Kirkness, Junhua Yu, Carl V. Asche. (2008) The Effect on Comorbidity and Pain in Patients with Osteoarthritis. Journal of Pain and Palliative Care Pharmacotherapy 22:4, 336-348
CrossRef169
U. Sechtem. (2008) Therapie der stabilen Angina pectoris. Der Internist 49:1, 57-68
CrossRef170
Carla R. Scanzello, Neal K. Moskowitz, Allan Gibofsky. (2007) The post-NSAID era: What to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis. Current Pain and Headache Reports 11:6, 415-422
CrossRef171
Milo C. Engoren, Robert H. Habib, Anoar Zacharias, John Dooner, Thomas A. Schwann, Christopher J. Riordan, Samuel J. Durham, Aamir Shah. (2007) Postoperative Analgesia With Ketorolac Is Associated With Decreased Mortality After Isolated Coronary Artery Bypass Graft Surgery in Patients Already Receiving Aspirin: A Propensity-Matched Study. Journal of Cardiothoracic and Vascular Anesthesia 21:6, 820-826
CrossRef172
Alejandro Escudero-Contreras, Janitzia Vazquez-Mellado Cervantes, Eduardo Collantes-Estevez. (2007) Update on the clinical pharmacology of etoricoxib, a potent cyclooxygenase-2 inhibitor. Future Rheumatology 2:6, 545-565
CrossRef173
Vibeke Strand. (2007) Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?. The Lancet 370:9605, 2138-2151
CrossRef174
Colin D Funk, Garret A FitzGerald. (2007) COX-2 Inhibitors and Cardiovascular Risk. Journal of Cardiovascular Pharmacology 50:5, 470-479
CrossRef175
Nauder Faraday, Diane M Becker, Lewis C Becker. (2007) Pharmacogenomics of platelet responsiveness to aspirin. Pharmacogenomics 8:10, 1413-1425
CrossRef176
(2007) Guía de Práctica Clínica para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST. Revista Española de Cardiología 60:10, 1070.e1-1070.e80
CrossRef177
Burkhard Hinz, Bertold Renner, Kay Brune. (2007) Drug Insight: cyclo-oxygenase-2 inhibitors—a critical appraisal. Nature Clinical Practice Rheumatology 3:10, 552-560
CrossRef178
T. Drews, F. Küpper, B. Stiller, M. Hübler, Y. Weng, F. Berger, R. Hetzer. (2007) Gerinnungsmanagement bei Kindern mit mechanischer Kreislaufunterstützung. Zeitschrift für Herz-,Thorax- und Gefäßchirurgie 21:5, 188-197
CrossRef179
Alan Matsumoto, Agustin Melian, Arvind Shah, Sean P. Curtis. (2007) Etoricoxib versus naproxen in patients with rheumatoid arthritis: a prospective, randomized, comparator-controlled 121-week trial. Current Medical Research and Opinion 23:9, 2259-2268
CrossRef180
Masaya Iwashita, Nobuaki Oka, Satoko Ohkubo, Masaki Saito, Norimichi Nakahata. (2007) Piperlongumine, a constituent of Piper longum L., inhibits rabbit platelet aggregation as a thromboxane A2 receptor antagonist. European Journal of Pharmacology 570:1-3, 38-42
CrossRef181
G. DE GAETANO, C. CERLETTI. (2007) Platelet function, antiplatelet therapy and clinical outcomes: to test or not to test?. Journal of Thrombosis and Haemostasis 5:9, 1835-1838
CrossRef182
Thorsten Drews, Brigitte Stiller, Michael Hübler, Yuguo Weng, Felix Berger, Roland Hetzer. (2007) Coagulation Management in Pediatric Mechanical Circulatory Support. ASAIO Journal 53:5, 640-645
CrossRef183
R.W. Moskowitz, S.B. Abramson, F. Berenbaum, L.S. Simon, M. Hochberg. (2007) Coxibs and NSAIDs – Is the air any clearer? Perspectives from the OARSI/International COX-2 Study Group Workshop 2007. Osteoarthritis and Cartilage 15:8, 849-856
CrossRef184
M. CATTANEO. (2007) Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. Journal of Thrombosis and Haemostasis 5, 230-237
CrossRef185
Garret A. FitzGerald. (2007) COX-2 in play at the AHA and the FDA. Trends in Pharmacological Sciences 28:7, 303-307
CrossRef186
B Duncan X Lascelles, Michael H Court, Elizabeth M Hardie, Sheilah A Robertson. (2007) Nonsteroidal anti-inflammatory drugs in cats: a review. Veterinary Anaesthesia and Analgesia 34:4, 228-250
CrossRef187
Alaa Rostom, Katherine Muir, Catherine Dubé, Emilie Jolicoeur, Michel Boucher, Janet Joyce, Peter Tugwell, George W. Wells. (2007) Gastrointestinal Safety of Cyclooxygenase-2 Inhibitors: A Cochrane Collaboration Systematic Review. Clinical Gastroenterology and Hepatology 5:7, 818-828.e5
CrossRef188
G. Cheng, J. Shan, G. Xu, P. Liu, Y. Zhou, Y. Zhu, X. Lu. (2007) Relationship between endothelial dysfunction, oxidant stress and aspirin resistance in patients with stable coronary heart disease. Journal of Clinical Pharmacy and Therapeutics 32:3, 287-292
CrossRef189
Jane W. Newburger, David R. Fulton. (2007) Kawasaki disease. Current Treatment Options in Cardiovascular Medicine 9:2, 148-158
CrossRef190
John K. Amory, David W. Amory. (2007) Dosing Frequency of Aspirin and Prevention of Heart Attacks and Strokes. The American Journal of Medicine 120:4, e5
CrossRef191
Feng Yang, Chuanbing Bian, Lili Zhu, Gengxiang Zhao, Zixiang Huang, Mingdong Huang. (2007) Effect of human serum albumin on drug metabolism: Structural evidence of esterase activity of human serum albumin. Journal of Structural Biology 157:2, 348-355
CrossRef192
Loren Laine, Sean P Curtis, Byron Cryer, Amarjot Kaur, Christopher P Cannon. (2007) Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. The Lancet 369:9560, 465-473
CrossRef193
Goksel Kahraman, Tayfun Sahin, Teoman Kilic, Nart Zafer Baytugan, Aysen Agacdiken, Ertan Ural, Dilek Ural, Baki Komsuoglu. (2007) The frequency of aspirin resistance and its risk factors in patients with metabolic syndrome. International Journal of Cardiology 115:3, 391-396
CrossRef194
John A. Cairns. (2007) The coxibs and traditional nonsteroidal anti-inflammatory drugs: A current perspective on cardiovascular risks. Canadian Journal of Cardiology 23:2, 125-131
CrossRef195
Jason Ellison, William Dager. (2007) Recent FDA Warning of the Concomitant Use of Aspirin and Ibuprofen and the Effects on Platelet Aggregation. Preventive Cardiology 10:2, 61-63
CrossRef196
Yutaka Kawahito. (2007) Clinical implications of cyclooxygenase-2 inhibitors. Inflammation and Regeneration 27:6, 552-558
CrossRef197
Elliot V. Hersh, Andres Pinto, Paul A. Moore. (2007) Adverse drug interactions involving common prescription and over-the-counter analgesic agents. Clinical Therapeutics 29:11, 2477-2497
CrossRef198
Xiaoxia Zheng, Hiroyuki Oda, Kayo Takamatsu, Yukio Sugimoto, Akihiro Tai, Eiichi Akaho, Hamed Ismail Ali, Toshiyuki Oshiki, Hiroki Kakuta, Kenji Sasaki. (2007) Analgesic agents without gastric damage: Design and synthesis of structurally simple benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors. Bioorganic & Medicinal Chemistry 15:2, 1014-1021
CrossRef199
Nicholas Moore. (2007) Diclofenac Potassium 12.5mg Tablets for Mild to Moderate Pain and Fever. Clinical Drug Investigation 27:3, 163-195
CrossRef200
Eduard Shantsila, Timothy Watson, Gregory Y.H. Lip*. (2007) Aspirin resistance: What, why and when?. Thrombosis Research 119:5, 551-554
CrossRef201
Marta L. Capone, Stefania Tacconelli, Luigia Di Francesco, Andrea Sacchetti, Maria G. Sciulli, Paola Patrignani. (2007) Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins & Other Lipid Mediators 82:1-4, 85-94
CrossRef202
Cagdas Ozdol, Sadi Gulec, Uzeyir Rahimov, Yusuf Atmaca, Sibel Turhan, Cetin Erol. (2007) Naproxen treatment prevents periprocedural inflammatory response but not myocardial injury after percutaneous coronary intervention. Thrombosis Research 119:4, 453-459
CrossRef203
Carlo Patrono, Bianca Rocca. (2007) Drug Insight: aspirin resistance—fact or fashion?. Nature Clinical Practice Cardiovascular Medicine 4:1, 42-50
CrossRef204
Jang-Young Kim, Junghan Yoon. (2007) Aspirin and Clopidogrel Resistance in Drug Eluting Stent Era. Korean Circulation Journal 37:4, 135
CrossRef205
Andrew Miller, Andrew McKee, C. David Mazer. 2007. Sedation, Analgesia, and Related Topics. , 53-70.
CrossRef206
Ignatius Gerardo E. Zarraga, Ernst R. Schwarz. (2007) Coxibs and Heart Disease. Journal of the American College of Cardiology 49:1, 1-14
CrossRef207
B. Hinz, K. Brune. (2007) Schmerztherapie mit antipyretischen Analgetika. Der Orthopäde 36:1, 23-31
CrossRef208
Huyen A. Tran, Sonia S. Anand, Graeme J. Hankey, John W. Eikelboom. (2007) Aspirin resistance. Thrombosis Research 120:3, 337-346
CrossRef209
D. J. Fitzgerald, A. Maree. (2007) Aspirin and Clopidogrel Resistance. Hematology 2007:1, 114-120
CrossRef210
Luis A. García Rodríguez, Antonio González-Péreza. (2007) Cardiovascular Safety of Non-Steroidal Anti-Inflammatory Drugs. Lights and Shadows. Reumatolog ía Cl ínica (English Edition) 3:3, 95-97
CrossRef211
Richard C. Becker. 2007. Hemostatic Aspects of Cardiovascular Medicine. , 339-369.
CrossRef212
Marie Lordkipanidzé, Chantal Pharand, Donald A. Palisaitis, Jean G. Diodati. (2006) Aspirin resistance: Truth or dare. Pharmacology & Therapeutics 112:3, 733-743
CrossRef213
Matthias Pfisterer, Hans Peter Brunner-La Rocca, Peter T. Buser, Peter Rickenbacher, Patrick Hunziker, Christian Mueller, Raban Jeger, Franziska Bader, Stefan Osswald, Christoph Kaiser. (2006) Late Clinical Events After Clopidogrel Discontinuation May Limit the Benefit of Drug-Eluting Stents. Journal of the American College of Cardiology 48:12, 2584-2591
CrossRef214
Wei C. Lau, Paul A. Gurbel. (2006) Antiplatelet Drug Resistance and Drug-Drug Interactions: Role of Cytochrome P450 3A4. Pharmaceutical Research 23:12, 2691-2708
CrossRef215
Paul A Lotke, Jess H Lonner. (2006) The Benefit of Aspirin Chemoprophylaxis for Thromboembolism after Total Knee Arthroplasty. Clinical Orthopaedics and Related Research 452, 175-180
CrossRef216
Luis Alberto García Rodríguez, Paola Patrignani. (2006) The ever growing story of cyclo-oxygenase inhibition. The Lancet 368:9549, 1745-1747
CrossRef217
Neal M Davies, Jonathon K Reynolds, Megan R Undeberg, Brian J Gates, Yusuke Ohgami, Karina R Vega-Villa. (2006) Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal. Expert Review of Neurotherapeutics 6:11, 1643-1655
CrossRef218
Christopher P Cannon, Sean P Curtis, Garret A FitzGerald, Henry Krum, Amarjot Kaur, James A Bolognese, Alise S Reicin, Claire Bombardier, Michael E Weinblatt, Désirée van der Heijde, Erland Erdmann, Loren Laine. (2006) Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. The Lancet 368:9549, 1771-1781
CrossRef219
2006. Chronic Low Back Pain. .
CrossRef220
Walter S. Schroeder, Linda Ghobrial, Pritesh J. Gandhi. (2006) Possible mechanisms of drug-induced aspirin and clopidogrel resistance. Journal of Thrombosis and Thrombolysis 22:2, 139-150
CrossRef221
James T. Willerson, Paul W Armstrong. 2006. Acute Myocardial Infarction. , 611-646.
CrossRef222
Tze-Zen Ong, Chris J. Hawkey, Khek-Yu Ho. (2006) Nonsteroidal Anti-inflammatory Drug Use Is a Significant Cause of Peptic Ulcer Disease in a Tertiary Hospital in Singapore: A Prospective Study. Journal of Clinical Gastroenterology 40:9, 795-800
CrossRef223
Thomas Hohlfeld. (2006) Aspirin-Resistenz / Aspirin resistance. LaboratoriumsMedizin 30:5, 302-309
CrossRef224
Karsten Schrör, T. Hohlfeld, A.-A. Weber. (2006) Aspirin resistance – does it clinically matter?. Clinical Research in Cardiology 95:10, 505-510
CrossRef225
Adnan K. Chhatriwalla, Deepak L. Bhatt. 2006. Anticoagulation and Antiplatelet Agents. , 501-524.
CrossRef226
Francis KL Chan. (2006) Primer: managing NSAID-induced ulcer complications—balancing gastrointestinal and cardiovascular risks. Nature Clinical Practice Gastroenterology & Hepatology 3:10, 563-573
CrossRef227
Alfio Bertolini, Anna Ferrari, Alessandra Ottani, Simona Guerzoni, Raffaella Tacchi, Sheila Leone. (2006) Paracetamol: New Vistas of an Old Drug. CNS Drug Reviews 12:3-4, 250-275
CrossRef228
Francesco Violi, Pasquale Pignatelli. (2006) Aspirin resistance: is this term meaningful?. Current Opinion in Hematology 13:5, 331-336
CrossRef229
Thao Pham, Laure Gossec, Arnaud Constantin, Stephan Pavy, Eric Bruckert, Alain Cantagrel, Bernard Combe, René-Marc Flipo, Philippe Goupille, Xavier Le Loët, Xavier Mariette, Xavier Puéchal, Thierry Schaeverbeke, Jean Sibilia, Jacques Tebib, Daniel Wendling, Maxime Dougados. (2006) Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 73:4, 379-387
CrossRef230
Zachary A Stacy, Paul P Dobesh, Toby C Trujillo. (2006) Cardiovascular Risks of Cyclooxygenase Inhibition. Pharmacotherapy 26:7, 919-938
CrossRef231
Matt Fisher, Volker Knappertz. (2006) The dose of aspirin for the prevention of cardiovascular and cerebrovascular events. Current Medical Research and Opinion 22:7, 1239-1248
CrossRef232
Richard M. Langford. (2006) Pain management today—what have we learned?. Clinical Rheumatology 25:S1, 2-8
CrossRef233
C. J. Hawkey, G. M. Hawkey, S. Everitt, M. M. Skelly, W. A. Stack, D. Gray. (2006) Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs. British Journal of Clinical Pharmacology 61:6, 730-737
CrossRef234
Vibeke Strand. (2006) Expectations From Patients With Rheumatoid Arthritis Regarding COX-2s: Cutting to the Heart of the Matter. Journal of Cardiovascular Pharmacology 47:Supplement 1, S55-S59
CrossRef235
J. L. GOLDSTEIN, S. C. LOWRY, F. L. LANZA, H. I. SCHWARTZ, W. E. DODGE. (2006) The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor. Alimentary Pharmacology and Therapeutics 23:10, 1489-1498
CrossRef236
Daniel H. Solomon, Jerry Avorn, Til Stürmer, Robert J. Glynn, Helen Mogun, Sebastian Schneeweiss. (2006) Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: High-risk subgroups and time course of risk. Arthritis & Rheumatism 54:5, 1378-1389
CrossRef237
Jan Steffel, Thomas F. L??scher, Frank Ruschitzka, Felix C. Tanner. (2006) Cyclooxygenase-2 Inhibition and Coagulation. Journal of Cardiovascular Pharmacology 47:Supplement 1, S15-S20
CrossRef238
Gina Rohekar, Arthur AM Bookman. (2006) Diclofenac sodium in the treatment of osteoarthritis. Aging Health 2:2, 179-187
CrossRef239
E. D. Michos, R. Ardehali, R. S. Blumenthal, R. A. Lange, H. Ardehali. (2006) Aspirin and Clopidogrel Resistance. Mayo Clinic Proceedings 81:4, 518-526
CrossRef240
Sonia Hernandez-Diaz, Cristina Varas-Lorenzo, Luis A. Garcia Rodriguez. (2006) Non-Steroidal Antiinflammatory Drugs and the Risk of Acute Myocardial Infarction. Basic <html_ent glyph="@amp;" ascii="&"/> Clinical Pharmacology <html_ent glyph="@amp;" ascii="&"/> Toxicology 98:3, 266-274
CrossRef241
S P H Alexander, A Mathie, J A Peters. (2006) Cyclooxygenase (E.C. 1.14.99.1). British Journal of PharmacologyS157-S157
CrossRef242
Thomas M. MacDonald, Li Wei. (2006) Is there an Interaction between the Cardiovascular Protective Effects of Low-Dose Aspirin and Ibuprofen?. Basic <html_ent glyph="@amp;" ascii="&"/> Clinical Pharmacology <html_ent glyph="@amp;" ascii="&"/> Toxicology 98:3, 275-280
CrossRef243
Karsten Schrör, Artur-Aron Weber, Thomas Hohlfeld. (2006) Aspirin “resistance”. Blood Cells, Molecules, and Diseases 36:2, 171-176
CrossRef244
Graeme J Hankey, John W Eikelboom. (2006) Aspirin resistance. The Lancet 367:9510, 606-617
CrossRef245
Ömer Nuri Pamuk, Necati Çakır. (2006) The renal effects of the addition of low-dose aspirin to COX-2 selective and nonselective antiinflammatory drugs. Clinical Rheumatology 25:1, 123-125
CrossRef246
Silvano Adami. (2006) Anti-inflammatory therapy and cardiovascular risk: new insights. Future Rheumatology 1:1, 7-10
CrossRef247
T. Drews, M. Jurmann, W. Pasic, Y. Weng, R. Hetzer. (2006) Gerinnungsmanagement von Patienten an einer mechanischen Kreislaufunterstützung. Zeitschrift für Herz-,Thorax- und Gefäßchirurgie 20:1, 21-28
CrossRef248
Costas Hanjis, William H. Frishman, Robert G. Lerner. (2006) Aspirin Resistance. Cardiology in Review 14:1, 18-25
CrossRef249
FAYEZ KOTOB, MARK J. LEMA. 2006. Nonopioid Analgesics. , 253-303.
CrossRef250
Gergely Feher, Katalin Koltai, Elod Papp, Balint Alkonyi, Alexander Solyom, Peter Kenyeres, Gabor Kesmarky, Laszlo Czopf, Kalman Toth. (2006) Aspirin Resistance. Drugs & Aging 23:7, 559-567
CrossRef251
Marc Maillard, Michel Burnier. (2006) Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs. Expert Opinion on Drug Safety 5:1, 83-94
CrossRef252
Judy T. Chen, Frank Pucino, Beth H. Resman-Targoff. (2006) Celecoxib versus a Non-Selective NSAID Plus Proton-Pump Inhibitor. Journal of Pain and Palliative Care Pharmacotherapy 20:4, 11-32
CrossRef253
Sasidhar Guthikonda, Neal S Kleiman. (2006) Is aspirin resistance valid?. Future Cardiology 2:1, 1-4
CrossRef254
2006. Ibuprofen. , 1709-1713.
CrossRef255
Patrono, Carlo, García Rodríguez, Luis A., Landolfi, Raffaele, Baigent, Colin, . (2005) Low-Dose Aspirin for the Prevention of Atherothrombosis. New England Journal of Medicine 353:22, 2373-2383
Full Text256
Gary W. Williams. (2005) An update on nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors. Current Pain and Headache Reports 9:6, 377-389
CrossRef257
Barry Bowen, Yuhong Yuan, Cindy James, Ferid Rashid, Richard H. Hunt. (2005) Time Course and Pattern of Blood Loss With Ibuprofen Treatment in Healthy Subjects. Clinical Gastroenterology and Hepatology 3:11, 1075-1082
CrossRef258
Tammy L. Burns, Aryan N. Mooss, Daniel E. Hilleman. (2005) Antiplatelet Drug Resistance: Not Ready for Prime Time. Pharmacotherapy 25:11, 1621-1628
CrossRef259
Robert J. Kaplan. (2005) Current Status of NonsteroidalAnti-Inflammatory Drugsin Physiatry. American Journal of Physical Medicine & Rehabilitation 84:11, 885-894
CrossRef260
Vijay Dhawan, David J. Schwalb, Matthew J. Shumway, Michael C. Warren, Roseanne S. Wexler, Irina S. Zemtseva, Brian M. Zifcak, David R. Janero. (2005) Selective nitros(yl)ation induced in vivo by a nitric oxide-donating cyclooxygenase-2 inhibitor: a NObonomic analysis. Free Radical Biology and Medicine 39:9, 1191-1207
CrossRef261
Andrew O. Maree, Ronan J. Curtin, Michelle Dooley, Ronan M. Conroy, Peter Crean, Dermot Cox, Desmond J. Fitzgerald. (2005) Platelet Response to Low-Dose Enteric-Coated Aspirin in Patients With Stable Cardiovascular Disease. Journal of the American College of Cardiology 46:7, 1258-1263
CrossRef262
Udaya S Tantry, Kevin P Bliden, Paul A Gurbel. (2005) Resistance to antiplatelet drugs: current status and future research. Expert Opinion on Pharmacotherapy 6:12, 2027-2045
CrossRef263
Lisa K. Stamp, Michael J. James, Leslie G. Cleland. (2005) Diet and Rheumatoid Arthritis: A Review of the Literature. Seminars in Arthritis and Rheumatism 35:2, 77-94
CrossRef264
Werner Kiefer, Gerd Dannhardt. (2005) COX-2 inhibition and pain management: a review summary. Expert Review of Clinical Immunology 1:3, 431-442
CrossRef265
J. M. SCHEIMAN, B. CRYER, M. ASAKA, F. BERENBAUM, J. BONNET, F. K.-L. CHAN, G. KREJS, A. LANAS, A. WEAVER, F. ZERBIB. (2005) Panel discussion: treatment approaches to control gastrointestinal risk and balance cardiovascular risks and benefits: proposals and recommendations. Alimentary Pharmacology & Therapeutics Symposium Series 1:1, 26-32
CrossRef266
A. L. WEAVER. (2005) Review article: aspirin, non-steroidal anti-inflammatory drugs and cyclo-oxygenase-1 sparing agents. Alimentary Pharmacology & Therapeutics Symposium Series 1:1, 2-5
CrossRef267
Giuseppe Faggian, Francesco Santini, Gianluigi Franchi, Peer M. Portner, Alessandro Mazzucco. (2005) Insights from Continued Use of a Novacor Left Ventricular Assist System for a Period of 6 Years. The Journal of Heart and Lung Transplantation 24:9, 1444.e17-1444.e19
CrossRef268
Mary Sarah Bergh, Steven C. Budsberg. (2005) The Coxib NSAIDs: Potential Clinical and Pharmacologic Importance in Veterinary Medicine. Journal of Veterinary Internal Medicine 19:5, 633-643
CrossRef269
Peter J. Mason, Alice K. Jacobs, Jane E. Freedman. (2005) Aspirin Resistance and Atherothrombotic Disease. Journal of the American College of Cardiology 46:6, 986-993
CrossRef270
F. BERENBAUM. (2005) Review article: clinical management of non-steroidal anti-inflammatory drug and cyclo-oxygenase-2 inhibitor users: a European perspective. Alimentary Pharmacology & Therapeutics Symposium Series 1:1, 6-10
CrossRef271
Michael H Kroll, Shuju Feng. (2005) Targeting shear stress-induced platelet activation: is lesion-specific antiplatelet therapy a realistic clinical goal?. Expert Review of Cardiovascular Therapy 3:5, 941-951
CrossRef272
Roberto Caporali, Marco A. Cimmino, Piercarlo Sarzi-Puttini, Raffaele Scarpa, Fabio Parazzini, Augusto Zaninelli, Alessandro Ciocci, Carlomaurizio Montecucco. (2005) Comorbid Conditions in the AMICA Study Patients: Effects on the Quality of Life and Drug Prescriptions by General Practitioners and Specialists. Seminars in Arthritis and Rheumatism 35:1, 31-37
CrossRef273
D. R. PHILLIPS, P. B. CONLEY, U. SINHA, P. ANDRE. (2005) Therapeutic approaches in arterial thrombosis. Journal of Thrombosis and Haemostasis 3:8, 1577-1589
CrossRef274
Aziz Maksoud, Robert C. Candipan, David B. Wilson, James L. Vacek. (2005) Aspirin and Clopidogrel: Efficacy, Treatment, and Resistance in Coronary Artery Disease. International Journal of Angiology 14:3, 109-114
CrossRef275
B. ROCCA, C. PATRONO. (2005) Determinants of the interindividual variability in response to antiplatelet drugs. Journal of Thrombosis and Haemostasis 3:8, 1597-1602
CrossRef276
Marta L Capone, Stefania Tacconelli, Paola Patrignani. (2005) Clinical pharmacology of etoricoxib. Expert Opinion on Drug Metabolism & Toxicology 1:2, 269-282
CrossRef277
A. SZCZEKLIK, J. MUSIAL, A. UNDAS, M. SANAK. (2005) Aspirin resistance. Journal of Thrombosis and Haemostasis 3:8, 1655-1662
CrossRef278
Sasidhar Guthikonda, Eli I. Lev, Neal S. Kleiman. (2005) Resistance to antiplatelet therapy. Current Cardiology Reports 7:4, 242-248
CrossRef279
Christopher P. Martin, Robert L. Talbert. (2005) Aspirin Resistance: An Evaluation of Current Evidence and Measurement Methods. Pharmacotherapy 25:7, 942-953
CrossRef280
Stewart M. Knoepp, Michael Laposata. (2005) Aspirin Resistance: Moving Forward With Multiple Definitions, Different Assays, and a Clinical Imperative. Pathology Patterns Reviews 123:1, S1-S8
CrossRef281
Gary Spektor, Valentin Fuster. (2005) Drug Insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk—where are we now?. Nature Clinical Practice Cardiovascular Medicine 2:6, 290-300
CrossRef282
Rosemarie A Reiter, Bernd Jilma. (2005) Platelets and new antiplatelet drugs. Therapy 2:3, 465-502
CrossRef283
Steven R. Steinhubl. (2005) The use of anti-inflammatory analgesics in the patient with cardiovascular disease. Journal of the American College of Cardiology 45:8, 1302-1303
CrossRef284
Ying Yu, Yan Cheng, Jinjin Fan, Xin-Sheng Chen, Andres Klein-Szanto, Garret A. FitzGerald, Colin D. Funk. (2005) Differential impact of prostaglandin H synthase 1 knockdown on platelets and parturition. Journal of Clinical Investigation 115:4, 986-995
CrossRef285
Marta L. Capone, Maria G. Sciulli, Stefania Tacconelli, Marilena Grana, Emanuela Ricciotti, Giulia Renda, Patrizia Di Gregorio, Gabriele Merciaro, Paola Patrignani. (2005) Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. Journal of the American College of Cardiology 45:8, 1295-1301
CrossRef286
Lorenz M. Fischer, Raymond G. Schlienger, Christian M. Matter, Hershel Jick, Christoph R. Meier. (2005) Current Use of Nonsteroidal Antiinflammatory Drugs and the Risk of Acute Myocardial Infarction. Pharmacotherapy 25:4, 503-510
CrossRef287
Ridker, Paul M, Cook, Nancy R., Lee, I-Min, Gordon, David, Gaziano, J. Michael, Manson, JoAnn E., Hennekens, Charles H., Buring, Julie E., . (2005) A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women. New England Journal of Medicine 352:13, 1293-1304
Full Text288
Frank A Beebe, Robert L Barkin, Stacie Barkin. (2005) A Clinical and Pharmacologic Review of Skeletal Muscle Relaxants for Musculoskeletal Conditions. American Journal of Therapeutics 12:2, 151-171
CrossRef289
Laszlo K. Sztriha, Katalin Sas, Laszlo Vecsei. (2005) Aspirin resistance in stroke: 2004. Journal of the Neurological Sciences 229-230, 163-169
CrossRef290
Jeffrey D. Greenberg, Clifton O. Bingham, Steven B. Abramson, George Reed, Rolf J. Sebaldt, Joel Kremer. (2005) Effect of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxygenase inhibitor among rheumatologists. Arthritis & Rheumatism 53:1, 12-17
CrossRef291
Byron Cryer, Roger G. Berlin, Stephen A. Cooper, Ching Hsu, Suman Wason. (2005) Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-tereated healthy adult volunteers. Clinical Therapeutics 27:2, 185-191
CrossRef292
Sheila A Doggrell. (2005) The safety of lumiracoxib when used in the treatment of arthritis. Expert Opinion on Pharmacotherapy 6:2, 347-350
CrossRef293
Gregory M. Peterson. (2005) Selecting Nonprescription Analgesics. American Journal of Therapeutics 12:1, 67-79
CrossRef294
Bryan PY Yan, David J Clark, Andrew E Ajani. (2005) Oral antiplatelet therapy and percutaneous coronary intervention. Expert Opinion on Pharmacotherapy 6:1, 3-12
CrossRef295
Ruth Savage. (2005) Cyclo-Oxygenase-2 Inhibitors. Drugs & Aging 22:3, 185-200
CrossRef296
Burkhard Hinz, Julia Chevts, Bertold Renner, Henrike Wuttke, Thomas Rau, Andreas Schmidt, Istvan Szelenyi, Kay Brune, Ulrike Werner. (2005) Bioavailability of diclofenac potassium at low doses. British Journal of Clinical Pharmacology 59:1, 80-84
CrossRef297
Enrique Bernal Morell, José Sabán Ruiz. (2005) Resistencia a la aspirina. Medicina Clínica 124:1, 30-36
CrossRef298
Marco Zimarino, Giulia Renda, Raffaele De Caterina. (2005) Optimal Duration of Antiplatelet Therapy in Recipients of Coronary Drug-Eluting Stents. Drugs 65:6, 725-732
CrossRef299
(2004) Rofecoxib, Merck, and the FDA. New England Journal of Medicine 351:27, 2875-2878
Full Text300
Raquel Garcia, Marta Benet, Catalina Arnau, Erik Cobo. (2004) Efficiency of the cross-over design: an empirical estimation. Statistics in Medicine 23:24, 3773-3780
CrossRef301
Anwar Umar, Michel Boisseau, Abdiryim Yusup, Halmurat Upur, Bernard Begaud, Nicholas Moore. (2004) Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. Fundamental and Clinical Pharmacology 18:5, 559-563
CrossRef302
Deborah Layton, Lynda V. Wilton, Saad A. W. Shakir. (2004) Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study. European Journal of Clinical Pharmacology 60:7, 489-501
CrossRef303
Tobias Kurth, Charles H. Hennekens, Julie E. Buring, J. Michael Gaziano. (2004) Aspirin, NSAIDs, and COX-2 inhibitors in cardiovascular disease: Possible interactions and implications for treatment of rheumatoid arthritis. Current Rheumatology Reports 6:5, 351-356
CrossRef304
Michael E Farkouh, Howard Kirshner, Robert A Harrington, Sean Ruland, Freek WA Verheugt, Thomas J Schnitzer, Gerd R Burmester, Eduardo Mysler, Marc C Hochberg, Michael Doherty, Elena Ehrsam, Xavier Gitton, Gerhard Krammer, Bernhard Mellein, Alberto Gimona, Patrice Matchaba, Christopher J Hawkey, James H Chesebro. (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. The Lancet 364:9435, 675-684
CrossRef305
Stefano Fiorucci, Andrea Mencarelli, Alessandra Meneguzzi, Alessandro Lechi, Barbara Renga, Piero del Soldato, Antonio Morelli, Pietro Minuz. (2004) Co-Administration of Nitric Oxide-Aspirin (NCX-4016) and Aspirin Prevents Platelet and Monocyte Activation and Protects Against Gastric Damage Induced by Aspirin in Humans. Journal of the American College of Cardiology 44:3, 635-641
CrossRef306
Garret A. FitzGerald. (2004) Prostaglandins. JCR: Journal of Clinical Rheumatology 10:Supplement, S12-S17
CrossRef307
F. K. L. Chan, D. Y. Graham. (2004) Prevention of non-steroidal anti-inflammatory drug gastrointestinal complications - review and recommendations based on risk assessment. Alimentary Pharmacology and Therapeutics 19:10, 1051-1061
CrossRef308
Aamir A. Cheema. (2004) Should People on Aspirin Avoid Ibuprofen?. Cardiology in Review 12:3, 174-176
CrossRef309
Judith L. Beizer, Michael Bottorff. (2004) Journal Review. The Consultant Pharmacist 19:5, 445-451
CrossRef310
Alex M. Blaicher, Harald T. Landsteiner, Olga Al-Falaki, Jochen Zwerina, Ivo Volf, Diego Gruber, Michael Zimpfer, Klaus Hoerauf. (2004) Acetylsalicylic Acid, Diclofenac, and Lornoxicam, but Not Rofecoxib, Affect Platelet CD 62 Expression. Anesthesia & Analgesia1082-1085
CrossRef311
Stephen E Kimmel, Jesse A Berlin, Muredach Reilly, Jane Jaskowiak, Lori Kishel, Jesse Chittams, Brian L Strom. (2004) The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. Journal of the American College of Cardiology 43:6, 985-990
CrossRef312
Deepak L Bhatt. (2004) Aspirin resistance: more than just a laboratory curiosity. Journal of the American College of Cardiology 43:6, 1127-1129
CrossRef313
Rob Hutchison. (2004) Pain Control:COX-2–Selective NSAIDs. AJN, American Journal of Nursing 104:3, 52-55
CrossRef314
Richard L Mueller. (2004) First-generation agents: aspirin, heparin and coumarins. Best Practice & Research Clinical Haematology 17:1, 23-53
CrossRef315
Jeptha P. Curtis, Harlan M. Krumholz. (2004) The case for an adverse interaction between aspirin and non-steroidal anti-inflammatory drugs. Journal of the American College of Cardiology 43:6, 991-993
CrossRef316
Patricia J. Neafsey. (2004) Self-Medication Practices That Alter the Efficacy of Selected Cardiac Medications. Home Healthcare Nurse: The Journal for the Home Care and Hospice Professional 22:2, 88-98
CrossRef317
Patricia A Howard, Patrice Delafontaine. (2004) Nonsteroidal Anti-Inflammatory drugs and cardiovascular risk. Journal of the American College of Cardiology 43:4, 519-525
CrossRef318
L Drouet. (2004) La résistance à l'aspirine existe-t-elle ?. La Revue de Médecine Interne 25:2, 101-103
CrossRef319
Babette B. Weksler. 2004. Antiplatelet Therapy for Secondary Prevention of Stroke. , 1107-1128.
CrossRef320
John W Eikelboom, Graeme J Hankey. (2004) Failure of Aspirin to Prevent Atherothrombosis. American Journal of Cardiovascular Drugs 4:1, 57-67
CrossRef321
John A Colwell. (2004) Antiplatelet Agents for the Prevention of Cardiovascular Disease in Diabetes Mellitus. American Journal of Cardiovascular Drugs 4:2, 87-106
CrossRef322
Caroline Fenton, Gillian M Keating, Antona J Wagstaff. (2004) Valdecoxib. Drugs 64:11, 1231-1261
CrossRef323
PATRICIA J. NEAFSEY. (2004) Low-Dose Aspirin Interactions. Home Healthcare Nurse: The Journal for the Home Care and Hospice Professional 22:1, 54-55
CrossRef324
David W J Clark, Deborah Layton, Saad A W Shakir. (2004) Do Some Inhibitors of COX-2 Increase the Risk of Thromboembolic Events?. Drug Safety 27:7, 427-456
CrossRef325
Mark J Alberts, Richard Atkinson. (2004) Risk Reduction Strategies in Ischaemic Stroke. Clinical Drug Investigation 24:5, 245-254
CrossRef326
William B White, Vibeke Strand, Richard Roberts, Andrew Whelton. (2004) Effects of the Cyclooxygenase-2 Specific Inhibitor Valdecoxib Versus Nonsteroidal Antiinflammatory Agents and Placebo on Cardiovascular Thrombotic Events in Patients with Arthritis. American Journal of Therapeutics 11:4, 244-250
CrossRef327
Yuhong Yuan, Richard H. Hunt. (2003) Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003?. InflammoPharmacology 11:4-6, 337-354
CrossRef328
David G. Silverman, Thomas Halaszynski, Raymond Sinatra, Martha Luther, Christine S. Binder. (2003) Rofecoxib does not compromise platelet aggregation during anesthesia and surgery. Canadian Journal of Anesthesia/Journal canadien d'anesthésie 50:10, 1004-1008
CrossRef329
P B Lockhart, J Gibson, S H Pond, J Leitch. (2003) Dental management considerations for the patient with an acquired coagulopathy. Part 2: Coagulopathies from drugs. British Dental Journal 195:9, 405-501
CrossRef330
Hani Jneid, Deepak L Bhatt. (2003) Advances in antiplatelet therapy. Expert Opinion on Emerging Drugs 8:2, 349-363
CrossRef331
Garret A. FitzGerald. (2003) COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nature Reviews Drug Discovery 2:11, 879-890
CrossRef332
Lawrence M Title, Karen Giddens, Michele M McInerney, Matthew J McQueen, Bassam A Nassar. (2003) Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. Journal of the American College of Cardiology 42:10, 1747-1753
CrossRef333
Olga Hatsiopoulou, Robert I. Cohen, Elvira V. Lang. (2003) Postprocedure Pain Management of Interventional Radiology Patients. Journal of Vascular and Interventional Radiology 14:11, 1373-1385
CrossRef334
Laura D Carbone, Frances A Tylavsky, Jane A Cauley, Tamara B Harris, Thomas F Lang, Douglas C Bauer, Karen D Barrow, Stephen B Kritchevsky. (2003) Association Between Bone Mineral Density and the Use of Nonsteroidal Anti-Inflammatory Drugs and Aspirin: Impact of Cyclooxygenase Selectivity. Journal of Bone and Mineral Research 18:10, 1795-1802
CrossRef335
Milo Engoren. (2003) Cost-effectiveness of different postoperative analgesic treatments. Expert Opinion on Pharmacotherapy 4:9, 1507-1519
CrossRef336
C. Patrono. (2003) Aspirin resistance: definition, mechanisms and clinical read-outs. Journal of Thrombosis and Haemostasis 1:8, 1710-1713
CrossRef337
Byron L. Cryer. (2003) Acetaminophen not associated with gastrointestinal toxicity: Comment on the article by Rahme et al. Arthritis & Rheumatism 48:7, 2074-2075
CrossRef338
Elham Rahme. (2003) Reply. Arthritis & Rheumatism 48:7, 2075-2077
CrossRef339
BRANISLAV SCHIFFERDECKER, DAVID H. SPODICK. (2003) Nonsteroidal Anti-inflammatory Drugs in the Treatment of Pericarditis. Cardiology in Review 11:4, 211-217
CrossRef340
(2003) Antiplatelet Therapy in Peripheral Arterial Disease. Consensus Statement. European Journal of Vascular and Endovascular Surgery 26:1, 1-16
CrossRef341
Paola Patrignani. (2003) Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. Thrombosis Research 110:5-6, 281-286
CrossRef342
M. Cattaneo. (2003) The platelet P2Y receptors as targets for new antithrombotic drugs. Journal of Thrombosis and Haemostasis 1:6, 1133-1135
CrossRef343
Noor M. Gajraj. (2003) Cyclooxygenase-2 Inhibitors. Anesthesia & Analgesia1720-1738
CrossRef344
Pamela L Cross. (2003) Effect of ibuprofen on cardioprotective effect of aspirin. The Lancet 361:9368, 1560-1561
CrossRef345
TM MacDonald, L Wei. (2003) Effect of ibuprofen on cardioprotective effect of aspirin. The Lancet 361:9368, 1559
CrossRef346
Garret FitzGerald. (2003) Effect of ibuprofen on cardioprotective effect of aspirin. The Lancet 361:9368, 1561
CrossRef347
Harvey J Weiss. (2003) Effect of ibuprofen on cardioprotective effect of aspirin. The Lancet 361:9368, 1560
CrossRef348
Francis Berenbaum. (2003) NSAIDs and aspirin: friends or foes?. Joint Bone Spine 70:2, 89-90
CrossRef349
TM MacDonald, L Wei. (2003) Effect of ibuprofen on cardioprotective effect of aspirin. The Lancet 361:9357, 573-574
CrossRef350
Garret A FitzGerald. (2003) Parsing an enigma: the pharmacodynamics of aspirin resistance. The Lancet 361:9357, 542-544
CrossRef351
Paola Patrignani, Marta L Capone, Stefania Tacconelli. (2003) Clinical pharmacology of etoricoxib: a novel selectiveCOX2 inhibitor. Expert Opinion on Pharmacotherapy 4:2, 265-284
CrossRef352
Maria G Sciulli, Francesca Seta, Stefania Tacconelli, Marta L Capone, Emanuela Ricciotti, Giuseppa Pistritto, Paola Patrignani. (2003) Effects of acetaminophen on constitutive and inducible prostanoid biosynthesis in human blood cells. British Journal of Pharmacology 138:4, 634-641
CrossRef353
Kenneth Brandt. (2003) Paracetamol in the Treatment of Osteoarthritis Pain. Drugs 63:Special Issue 2, 23-38
CrossRef354
Timo E Strandberg, Kaisu H Pitkala, Reijo S Tilvis. (2003) Benefits of Optimising Drug Treatment in Home-Dwelling Elderly Patients with Coronary Artery Disease. Drugs & Aging 20:8, 585-595
CrossRef355
Peter R. Holt. (2003) Gastrointestinal diseases in the elderly. Current Opinion in Clinical Nutrition and Metabolic Care 6:1, 41-48
CrossRef356
Robert E. Fowles. (2003) Potential Cardiovascular Effects of COX-2 Selective Nonsteroidal Antiinflammatory Drugs. Journal of Pain and Palliative Care Pharmacotherapy 17:2, 27-50
CrossRef357
Archibald McNicol, Sara J. Israels. (2003) Platelets and Anti-platelet Therapy. Journal of Pharmacological Sciences 93:4, 381-396
CrossRef358
Neal M Davies, Xiao W Teng, Neil M Skjodt. (2003) Pharmacokinetics of Rofecoxib. Clinical Pharmacokinetics 42:6, 545-556
CrossRef359
Nailin Li, Hu Hu, Paul Hjemdahl. (2003) Aspirin treatment does not attenuate platelet or leukocyte activation as monitored by whole blood flow cytometry. Thrombosis Research 111:3, 165-170
CrossRef360
Elham Rahme, Dan Pettitt, Jacques LeLorier. (2002) Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population. Arthritis & Rheumatism 46:11, 3046-3054
CrossRef361
Jos
L. Pablos. (2002) Aspirin antiplatelet therapy and nonsteroidal antiinflammatory drugs: Comment on the 2002 update of the American College of Rheumatology Guidelines for the Management of Rheumatoid Arthritis. Arthritis & Rheumatism 46:11, 3102-3102
CrossRef362
Steven B. Abramson. (2002) Et tu, acetaminophen?. Arthritis & Rheumatism 46:11, 2831-2835
CrossRef363
C. Kent Kwoh, Larry G. Anderson, Jerry M. Greene, Dorothy A. Johnson, James R. O'Dell, Mark L. Robbins, W. Neal Roberts, Robert W. Simms, Robert A. Yood. (2002) Reply. Arthritis & Rheumatism 46:11, 3103-3104
CrossRef364
Tali Burde, Gilad Rimon. (2002) On the interaction of specific prostaglandin H synthase-2 inhibitors with prostaglandin H synthase-1. European Journal of Pharmacology 453:2-3, 167-173
CrossRef365
CATHY M. FOMOUS, REBECCA B. COSTELLO, PAUL M. COATES. (2002) Symposium: conference on the science and policy of performance-enhancing products. Medicine & Science in Sports & Exercise 34:10, 1685-1690
CrossRef366
MacRae F. Linton, Sergio Fazio. (2002) Cyclooxygenase-2 and atherosclerosis. Current Opinion in Lipidology 13:5, 497-504
CrossRef367
Joseph Ming Wah Li. (2002) Pain management in the hospitalized patient. Medical Clinics of North America 86:4, 771-795
CrossRef368
. (2002) Effect van ibuprofen op de cardioprotectieve werking van lage doses acetylsalicylzuur. Medisch-Farmaceutische Mededelingen 40:9, 269-270
CrossRef369
Vibeke Strand, Marc C. Hochberg. (2002) The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. Arthritis & Rheumatism 47:4, 349-355
CrossRef370
Lawrence J Marnett. (2002) Recent developments in cyclooxygenase inhibition. Prostaglandins & Other Lipid Mediators 68-69, 153-164
CrossRef371
Peng Thim FAN. (2002) The Feng Pao Hsii Lecture. APLAR Journal of Rheumatology 5:1, 41-47
CrossRef372
Tarek A Samad, Adam Sapirstein, Clifford J Woolf. (2002) Prostanoids and pain: unraveling mechanisms and revealing therapeutic targets. Trends in Molecular Medicine 8:8, 390-396
CrossRef373
Joseph A. Markenson. (2002) The Demographics of Chronic Pain Management. Journal of Pain and Symptom Management 24:1, S10-S17
CrossRef374
Rainer Amann, Bernhard A Peskar. (2002) Anti-inflammatory effects of aspirin and sodium salicylate. European Journal of Pharmacology 447:1, 1-9
CrossRef375
(2002) Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin. New England Journal of Medicine 346:20, 1589-1590
Full Text376
Leslie J. Crofford. (2002) Specific cyclooxygenase-2 inhibitors: what have we learned since they came into widespread clinical use?. Current Opinion in Rheumatology 14:3, 225-230
CrossRef377
Arnaud Chiolero, Michel Burnier, Marc P Maillard. (2002) Cardiovascular hazard of selective COX-2 inhibitors: myth or reality?. Expert Opinion on Drug Safety 1:1, 45-52
CrossRef378
Thais Brown Tonore, Deborah S. King, Sara L. Noble. (2002) Do Over-the-counter medications for migraine hinder the physician?. Current Pain and Headache Reports 6:2, 162-167
CrossRef379
Arthur L. Weaver. (2002) Commentary. Journal of Pain and Symptom Management 23:4, S31-S34
CrossRef380
&NA;. (2002) Ibuprofen inhibits antiplatelet effects of aspirin?. Reactions Weekly &NA;:884, 4
CrossRef381
Stefania Tacconelli, Marta L. Capone, Maria G. Sciulli, Emanuela Ricciotti, Paola Patrignani. (2002) The Biochemical Selectivity of Novel COX-2 Inhibitors in Whole Blood Assays of COX-isozyme Activity. Current Medical Research and Opinion 18:8, 503-511
CrossRef382
Ronald S. MacWalter, Colin P. Shirley. (2002) A Benefit-Risk Assessment of Agents Used in the Secondary Prevention of Stroke. Drug Safety 25:13, 943-963
CrossRef383
Crofford, Leslie J., . (2001) Rational Use of Analgesic and Antiinflammatory Drugs. New England Journal of Medicine 345:25, 1844-1846
Full Text
- Letters
